

HPTN 083 – A Phase 2b/3 Double Blind Safety and Efficacy Study of Injectable Cabotegravir Compared to Daily Oral Tenofovir Disoproxil Fumarate/ Emtricitabine (TDF/FTC), For Pre-Exposure Prophylaxis in HIV-Uninfected Cisgender Men and Transgender Women who have Sex with Men
LIVE Open Report – March 5, 2026
Visit Cutoff Date: March 5, 2026

Table O7 – Visit Completion by Visit and Region ¹

	Overall	US	Latin America	Asia	Africa
Step 1					
Total participants enrolled ²	4566	1698	1964	752	152
Week 2	4404/4531 (97.2%)	1638/1683 (97.3%)	1881/1948 (96.6%)	742/750 (98.9%)	143/150 (95.3%)
Week 4	4373/4449 (98.3%)	1610/1641 (98.1%)	1885/1920 (98.2%)	738/741 (99.6%)	140/147 (95.2%)
Step 2					
Week 5 (Injection #1)	4199/4207 (99.8%)	1523/1525 (99.9%)	1815/1821 (99.7%)	732/732 (100.0%)	129/129 (100.0%)
1 week post-injection	4166/4205 (99.1%)	1517/1524 (99.5%)	1803/1820 (99.1%)	718/732 (98.1%)	128/129 (99.2%)
Week 9 (Injection #2)	4075/4173 (97.7%)	1486/1510 (98.4%)	1745/1808 (96.5%)	722/727 (99.3%)	122/128 (95.3%)
1 week post-injection	4024/4148 (97.0%)	1472/1498 (98.3%)	1725/1799 (95.9%)	711/725 (98.1%)	116/126 (92.1%)
Week 17 (Injection #3)	3920/4085 (96.0%)	1411/1462 (96.5%)	1683/1776 (94.8%)	711/723 (98.3%)	115/124 (92.7%)
2 weeks post-injection	3857/4038 (95.5%)	1397/1438 (97.1%)	1648/1760 (93.6%)	703/716 (98.2%)	109/124 (87.9%)
Week 25 (Injection #4)	3789/3988 (95.0%)	1363/1409 (96.7%)	1613/1743 (92.5%)	695/712 (97.6%)	118/124 (95.2%)
2 weeks post-injection	3701/3946 (93.8%)	1343/1392 (96.5%)	1569/1728 (90.8%)	681/705 (96.6%)	108/121 (89.3%)
Week 33 (Injection #5)	3672/3901 (94.1%)	1324/1378 (96.1%)	1562/1709 (91.4%)	676/695 (97.3%)	110/119 (92.4%)
2 weeks post-injection	3521/3880 (90.7%)	1310/1371 (95.6%)	1448/1699 (85.2%)	658/692 (95.1%)	105/118 (89.0%)
Week 41 (Injection #6)	3560/3854 (92.4%)	1288/1359 (94.8%)	1496/1689 (88.6%)	668/689 (97.0%)	108/117 (92.3%)
2 weeks post-injection	3230/3813 (84.7%)	1269/1345 (94.3%)	1220/1674 (72.9%)	642/678 (94.7%)	99/116 (85.3%)
Week 49 (Injection #7)	3411/3773 (90.4%)	1249/1327 (94.1%)	1402/1657 (84.6%)	651/674 (96.6%)	109/115 (94.8%)
2 weeks post-injection	2926/3740 (78.2%)	1235/1315 (93.9%)	984/1645 (59.8%)	615/667 (92.2%)	92/113 (81.4%)
Week 57 (Injection #8)	3380/3705 (91.2%)	1215/1297 (93.7%)	1434/1635 (87.7%)	627/664 (94.4%)	104/109 (95.4%)
2 weeks post-injection	2705/3668 (73.7%)	1194/1283 (93.1%)	854/1618 (52.8%)	577/658 (87.7%)	80/109 (73.4%)
Week 65 (Injection #9)	3269/3651 (89.5%)	1165/1271 (91.7%)	1380/1613 (85.6%)	624/658 (94.8%)	100/109 (91.7%)
2 weeks post-injection	2437/3605 (67.6%)	1137/1258 (90.4%)	689/1591 (43.3%)	535/647 (82.7%)	76/109 (69.7%)
Week 73 (Injection #10)	3083/3577 (86.2%)	1121/1239 (90.5%)	1251/1585 (78.9%)	611/645 (94.7%)	100/108 (92.6%)
2 weeks post-injection	2064/3547 (58.2%)	1053/1229 (85.7%)	479/1571 (30.5%)	464/641 (72.4%)	68/106 (64.2%)
Week 81 (Injection #11)	3039/3530 (86.1%)	1089/1218 (89.4%)	1252/1568 (79.8%)	603/639 (94.4%)	95/105 (90.5%)
2 weeks post-injection	1808/3491 (51.8%)	973/1212 (80.3%)	377/1543 (24.4%)	398/632 (63.0%)	60/104 (57.7%)
Week 89 (Injection #12)	3007/3478 (86.5%)	1057/1206 (87.6%)	1269/1537 (82.6%)	589/631 (93.3%)	92/104 (88.5%)
2 weeks post-injection	1504/3442 (43.7%)	871/1190 (73.2%)	259/1521 (17.0%)	329/627 (52.5%)	45/104 (43.3%)
Week 97 (Injection #13)	2829/3414 (82.9%)	1019/1173 (86.9%)	1135/1514 (75.0%)	585/624 (93.8%)	90/103 (87.4%)
2 weeks post-injection	1217/3382 (36.0%)	785/1160 (67.7%)	115/1502 (7.7%)	281/618 (45.5%)	36/102 (35.3%)
Week 105 (Injection #14)	2663/3368 (79.1%)	977/1149 (85.0%)	1046/1500 (69.7%)	561/617 (90.9%)	79/102 (77.5%)
2 weeks post-injection	954/3332 (28.6%)	689/1137 (60.6%)	50/1484 (3.4%)	198/609 (32.5%)	17/102 (16.7%)
Week 113 (Injection #15)	2505/3320 (75.5%)	923/1130 (81.7%)	975/1479 (65.9%)	542/609 (89.0%)	65/102 (63.7%)

¹ "Visit Completion" is defined as the number (and %) of participants who completed the visit among the participants who are expected according to the protocol schedule, plus any participants who have completed the visit even though their visit window has not yet closed. "Expected according to the protocol schedule" in step 2 refers to all participants who are active (Alive, HIV uninfected, have not permanently discontinued randomized study product, and not terminated from study) at the time of the visit and the visit window has closed. Participants who transitioned early to step 3 or annual follow-up are "expected" if they are alive, HIV un-infected and not terminated from the study at the time of the visit and the visit window has closed.

² Inappropriately enrolled participants and participants with invalid ID due to duplicate screening or enrollment are excluded.

HPTN 083 – A Phase 2b/3 Double Blind Safety and Efficacy Study of Injectable Cabotegravir Compared to Daily Oral Tenofovir Disoproxil Fumarate/ Emtricitabine (TDF/FTC), For Pre-Exposure Prophylaxis in HIV-Uninfected Cisgender Men and Transgender Women who have Sex with Men
LIVE Open Report – March 5, 2026
Visit Cutoff Date: March 5, 2026

Table O7 – Visit Completion by Visit and Region ¹

	Overall	US	Latin America	Asia	Africa
2 weeks post-injection	770/3289 (23.4%)	591/1114 (53.1%)	23/1467 (1.6%)	145/606 (23.9%)	11/102 (10.8%)
Week 121 (Injection #16)	2328/3281 (71.0%)	882/1106 (79.7%)	861/1467 (58.7%)	525/606 (86.6%)	60/102 (58.8%)
2 weeks post-injection	600/3254 (18.4%)	489/1096 (44.6%)	7/1458 (0.5%)	96/599 (16.0%)	8/101 (7.9%)
Week 129 (Injection #17)	2126/3239 (65.6%)	820/1084 (75.6%)	762/1457 (52.3%)	485/597 (81.2%)	59/101 (58.4%)
2 weeks post-injection	460/3201 (14.4%)	400/1069 (37.4%)	0/1439 (0.0%)	57/593 (9.6%)	3/100 (3.0%)
Week 137 (Injection #18)	1935/3174 (61.0%)	730/1061 (68.8%)	706/1425 (49.5%)	445/593 (75.0%)	54/95 (56.8%)
2 weeks post-injection	313/3126 (10.0%)	290/1039 (27.9%)	0/1414 (0.0%)	23/578 (4.0%)	0/95 (0.0%)
Week 145 (Injection #19)	1707/3112 (54.9%)	634/1027 (61.7%)	617/1412 (43.7%)	410/578 (70.9%)	46/95 (48.4%)
2 weeks post-injection	195/3073 (6.3%)	193/1012 (19.1%)	0/1398 (0.0%)	2/568 (0.4%)	0/95 (0.0%)
Week 153 (Injection #20)	1489/3057 (48.7%)	567/996 (56.9%)	525/1398 (37.6%)	354/568 (62.3%)	43/95 (45.3%)
2 weeks post-injection	13/2951 (0.4%)	13/947 (1.4%)	0/1357 (0.0%)	0/552 (0.0%)	0/95 (0.0%)
Week 161 (Injection #21)	3/2857 (0.1%)	3/946 (0.3%)	0/1269 (0.0%)	0/547 (0.0%)	0/95 (0.0%)
2 weeks post-injection	0/2766 (0.0%)	0/946 (0.0%)	0/1189 (0.0%)	0/536 (0.0%)	0/95 (0.0%)
Step 3 (Open-label TDF/FTC)					
Step 3 Week 12	1544/2041 (75.6%)	664/870 (76.3%)	503/664 (75.8%)	350/457 (76.6%)	27/50 (54.0%)
Step 3 Week 24	1224/1927 (63.5%)	550/844 (65.2%)	367/583 (63.0%)	291/451 (64.5%)	16/49 (32.7%)
Step 3 Week 36	929/1806 (51.4%)	400/810 (49.4%)	304/526 (57.8%)	217/424 (51.2%)	8/46 (17.4%)
Step 3 Week 48	594/1632 (36.4%)	259/783 (33.1%)	253/451 (56.1%)	78/353 (22.1%)	4/45 (8.9%)
Annual Follow-up					
Yearly visit 1	195/433 (45.0%)	82/235 (34.9%)	82/152 (53.9%)	30/44 (68.2%)	1/2 (50.0%)
Yearly visit 2	88/227 (38.8%)	38/106 (35.8%)	37/97 (38.1%)	13/22 (59.1%)	0/2 (0.0%)
Yearly visit 3	28/93 (30.1%)	9/38 (23.7%)	17/44 (38.6%)	2/10 (20.0%)	0/1 (0.0%)
Yearly visit 4	0/8 (0.0%)	0/5 (0.0%)	0/0 (-%)	0/3 (0.0%)	0/0 (-%)
All visits					
Number of visits completed	118586/185324 (64.0%)	47161/65983 (71.5%)	45091/79592 (56.7%)	22883/34044 (67.2%)	3451/5705 (60.5%)

¹ "Visit Completion" is defined as the number (and %) of participants who completed the visit among the participants who are expected according to the protocol schedule, plus any participants who have completed the visit even though their visit window has not yet closed. "Expected according to the protocol schedule" in step 2 refers to all participants who are active (Alive, HIV uninfected, have not permanently discontinued randomized study product, and not terminated from study) at the time of the visit and the visit window has closed. Participants who transitioned early to step 3 or annual follow-up are "expected" if they are alive, HIV uninfected and not terminated from the study at the time of the visit and the visit window has closed.

² Inappropriately enrolled participants and participants with invalid ID due to duplicate screening or enrollment are excluded.

HPTN 083 – A Phase 2b/3 Double Blind Safety and Efficacy Study of Injectable Cabotegravir Compared to Daily Oral Tenofovir Disoproxil Fumarate/ Emtricitabine (TDF/FTC), For Pre-Exposure Prophylaxis in HIV-Uninfected Cisgender Men and Transgender Women who have Sex with Men
LIVE Open Report – March 5, 2026
Visit Cutoff Date: March 5, 2026

Table O7A – Visit Completion by Visit and Site – Region: US ¹

	Overall	Atlanta	Aurora	Baltimore	Birmingham	Boston	Bronx
Step 1							
Total participants enrolled ²	1698	35	63	26	62	81	66
Week 2	1638/1683 (97.3%)	33/34 (97.1%)	63/63 (100.0%)	25/25 (100.0%)	61/62 (98.4%)	81/81 (100.0%)	64/65 (98.5%)
Week 4	1610/1641 (98.1%)	30/34 (88.2%)	57/57 (100.0%)	25/25 (100.0%)	60/61 (98.4%)	80/80 (100.0%)	61/62 (98.4%)
Step 2							
Week 5 (Injection #1)	1523/1525 (99.9%)	30/30 (100.0%)	51/51 (100.0%)	23/23 (100.0%)	60/60 (100.0%)	76/76 (100.0%)	54/54 (100.0%)
1 week post-injection	1517/1524 (99.5%)	30/30 (100.0%)	51/51 (100.0%)	23/23 (100.0%)	60/60 (100.0%)	74/76 (97.4%)	54/54 (100.0%)
Week 9 (Injection #2)	1486/1510 (98.4%)	28/30 (93.3%)	50/51 (98.0%)	21/21 (100.0%)	59/60 (98.3%)	72/74 (97.3%)	53/54 (98.1%)
1 week post-injection	1472/1498 (98.3%)	27/29 (93.1%)	50/51 (98.0%)	21/21 (100.0%)	57/59 (96.6%)	72/74 (97.3%)	53/53 (100.0%)
Week 17 (Injection #3)	1411/1462 (96.5%)	26/29 (89.7%)	50/50 (100.0%)	19/21 (90.5%)	54/58 (93.1%)	69/72 (95.8%)	50/53 (94.3%)
2 weeks post-injection	1397/1438 (97.1%)	26/28 (92.9%)	49/50 (98.0%)	19/20 (95.0%)	54/56 (96.4%)	69/72 (95.8%)	50/52 (96.2%)
Week 25 (Injection #4)	1363/1409 (96.7%)	26/27 (96.3%)	48/49 (98.0%)	17/19 (89.5%)	51/52 (98.1%)	67/71 (94.4%)	47/48 (97.9%)
2 weeks post-injection	1343/1392 (96.5%)	25/26 (96.2%)	47/48 (97.9%)	16/18 (88.9%)	51/52 (98.1%)	66/69 (95.7%)	46/48 (95.8%)
Week 33 (Injection #5)	1324/1378 (96.1%)	24/25 (96.0%)	46/48 (95.8%)	14/17 (82.4%)	51/52 (98.1%)	65/67 (97.0%)	46/48 (95.8%)
2 weeks post-injection	1310/1371 (95.6%)	24/24 (100.0%)	46/48 (95.8%)	13/17 (76.5%)	51/52 (98.1%)	64/67 (95.5%)	46/48 (95.8%)
Week 41 (Injection #6)	1288/1359 (94.8%)	23/23 (100.0%)	44/47 (93.6%)	14/17 (82.4%)	51/52 (98.1%)	61/65 (93.8%)	46/48 (95.8%)
2 weeks post-injection	1269/1345 (94.3%)	23/23 (100.0%)	44/47 (93.6%)	14/17 (82.4%)	50/51 (98.0%)	60/65 (92.3%)	46/48 (95.8%)
Week 49 (Injection #7)	1249/1327 (94.1%)	22/22 (100.0%)	44/47 (93.6%)	12/16 (75.0%)	48/51 (94.1%)	60/63 (95.2%)	45/47 (95.7%)
2 weeks post-injection	1235/1315 (93.9%)	22/22 (100.0%)	44/47 (93.6%)	12/16 (75.0%)	48/51 (94.1%)	60/62 (96.8%)	44/46 (95.7%)
Week 57 (Injection #8)	1215/1297 (93.7%)	22/22 (100.0%)	42/45 (93.3%)	12/15 (80.0%)	49/50 (98.0%)	58/61 (95.1%)	43/45 (95.6%)
2 weeks post-injection	1194/1283 (93.1%)	20/21 (95.2%)	42/45 (93.3%)	12/15 (80.0%)	47/50 (94.0%)	56/58 (96.6%)	43/45 (95.6%)
Week 65 (Injection #9)	1165/1271 (91.7%)	17/20 (85.0%)	41/45 (91.1%)	11/14 (78.6%)	46/49 (93.9%)	56/58 (96.6%)	43/44 (97.7%)
2 weeks post-injection	1137/1258 (90.4%)	15/20 (75.0%)	39/45 (86.7%)	11/14 (78.6%)	46/49 (93.9%)	56/58 (96.6%)	41/43 (95.3%)
Week 73 (Injection #10)	1121/1239 (90.5%)	14/20 (70.0%)	41/44 (93.2%)	8/13 (61.5%)	48/49 (98.0%)	54/57 (94.7%)	41/42 (97.6%)
2 weeks post-injection	1053/1229 (85.7%)	12/19 (63.2%)	38/44 (86.4%)	7/12 (58.3%)	47/49 (95.9%)	52/57 (91.2%)	32/42 (76.2%)
Week 81 (Injection #11)	1089/1218 (89.4%)	13/18 (72.2%)	39/44 (88.6%)	6/12 (50.0%)	46/47 (97.9%)	55/57 (96.5%)	40/41 (97.6%)
2 weeks post-injection	973/1212 (80.3%)	10/17 (58.8%)	36/44 (81.8%)	6/12 (50.0%)	42/47 (89.4%)	50/57 (87.7%)	27/40 (67.5%)
Week 89 (Injection #12)	1057/1206 (87.6%)	12/17 (70.6%)	39/43 (90.7%)	6/12 (50.0%)	46/47 (97.9%)	52/57 (91.2%)	35/39 (89.7%)
2 weeks post-injection	871/1190 (73.2%)	8/17 (47.1%)	30/42 (71.4%)	5/11 (45.5%)	41/47 (87.2%)	47/57 (82.5%)	21/36 (58.3%)
Week 97 (Injection #13)	1019/1173 (86.9%)	10/16 (62.5%)	34/41 (82.9%)	5/11 (45.5%)	47/47 (100.0%)	54/57 (94.7%)	31/36 (86.1%)
2 weeks post-injection	785/1160 (67.7%)	6/16 (37.5%)	25/40 (62.5%)	5/11 (45.5%)	40/45 (88.9%)	44/57 (77.2%)	20/36 (55.6%)
Week 105 (Injection #14)	977/1149 (85.0%)	11/15 (73.3%)	34/39 (87.2%)	6/11 (54.5%)	45/45 (100.0%)	53/57 (93.0%)	28/36 (77.8%)
2 weeks post-injection	689/1137 (60.6%)	5/15 (33.3%)	19/39 (48.7%)	5/10 (50.0%)	38/45 (84.4%)	43/57 (75.4%)	14/36 (38.9%)
Week 113 (Injection #15)	923/1130 (81.7%)	8/14 (57.1%)	32/39 (82.1%)	6/10 (60.0%)	45/45 (100.0%)	47/57 (82.5%)	28/36 (77.8%)

¹ "Visit Completion" is defined as the number (and %) of participants who completed the visit among the participants who are expected according to the protocol schedule, plus any participants who have completed the visit even though their visit window has not yet closed. "Expected according to the protocol schedule" in step 2 refers to all participants who are active (Alive, HIV uninfected, have not permanently discontinued randomized study product, and not terminated from study) at the time of the visit and the visit window has closed. Participants who transitioned early to step 3 or annual follow-up are "expected" if they are alive, HIV uninfected and not terminated from the study at the time of the visit and the visit window has closed.

² Inappropriately enrolled participants and participants with invalid ID due to duplicate screening or enrollment are excluded.

HPTN 083 – A Phase 2b/3 Double Blind Safety and Efficacy Study of Injectable Cabotegravir Compared to Daily Oral Tenofovir Disoproxil Fumarate/ Emtricitabine (TDF/FTC), For Pre-Exposure Prophylaxis in HIV-Uninfected Cisgender Men and Transgender Women who have Sex with Men
LIVE Open Report – March 5, 2026
Visit Cutoff Date: March 5, 2026

Table O7A – Visit Completion by Visit and Site – Region: US ¹

	Overall	Atlanta	Aurora	Baltimore	Birmingham	Boston	Bronx
2 weeks post-injection	591/1114 (53.1%)	2/12 (16.7%)	16/39 (41.0%)	5/10 (50.0%)	33/45 (73.3%)	37/57 (64.9%)	12/36 (33.3%)
Week 121 (Injection #16)	882/1106 (79.7%)	6/12 (50.0%)	28/39 (71.8%)	5/10 (50.0%)	43/45 (95.6%)	49/56 (87.5%)	22/36 (61.1%)
2 weeks post-injection	489/1096 (44.6%)	1/12 (8.3%)	12/39 (30.8%)	3/10 (30.0%)	27/45 (60.0%)	30/56 (53.6%)	8/35 (22.9%)
Week 129 (Injection #17)	820/1084 (75.6%)	4/12 (33.3%)	27/38 (71.1%)	5/10 (50.0%)	42/45 (93.3%)	45/53 (84.9%)	18/35 (51.4%)
2 weeks post-injection	400/1069 (37.4%)	0/10 (0.0%)	7/38 (18.4%)	3/9 (33.3%)	21/43 (48.8%)	23/51 (45.1%)	7/35 (20.0%)
Week 137 (Injection #18)	730/1061 (68.8%)	2/10 (20.0%)	23/37 (62.2%)	5/9 (55.6%)	38/43 (88.4%)	35/51 (68.6%)	15/35 (42.9%)
2 weeks post-injection	290/1039 (27.9%)	0/10 (0.0%)	4/37 (10.8%)	2/9 (22.2%)	18/41 (43.9%)	12/51 (23.5%)	4/35 (11.4%)
Week 145 (Injection #19)	634/1027 (61.7%)	3/10 (30.0%)	23/37 (62.2%)	5/9 (55.6%)	36/41 (87.8%)	34/50 (68.0%)	14/34 (41.2%)
2 weeks post-injection	193/1012 (19.1%)	0/10 (0.0%)	2/34 (5.9%)	1/9 (11.1%)	15/41 (36.6%)	4/46 (8.7%)	3/34 (8.8%)
Week 153 (Injection #20)	567/996 (56.9%)	2/10 (20.0%)	18/34 (52.9%)	4/9 (44.4%)	34/41 (82.9%)	25/42 (59.5%)	11/34 (32.4%)
2 weeks post-injection	13/947 (1.4%)	0/9 (0.0%)	0/26 (0.0%)	0/8 (0.0%)	1/41 (2.4%)	0/41 (0.0%)	0/34 (0.0%)
Week 161 (Injection #21)	3/946 (0.3%)	0/9 (0.0%)	0/26 (0.0%)	0/8 (0.0%)	0/41 (0.0%)	0/41 (0.0%)	0/34 (0.0%)
2 weeks post-injection	0/946 (0.0%)	0/9 (0.0%)	0/26 (0.0%)	0/8 (0.0%)	0/41 (0.0%)	0/41 (0.0%)	0/34 (0.0%)
Step 3 (Open-label TDF/FTC)							
Step 3 Week 12	664/870 (76.3%)	6/8 (75.0%)	16/27 (59.3%)	7/14 (50.0%)	37/46 (80.4%)	45/54 (83.3%)	14/27 (51.9%)
Step 3 Week 24	550/844 (65.2%)	4/7 (57.1%)	12/26 (46.2%)	7/14 (50.0%)	30/44 (68.2%)	39/52 (75.0%)	13/27 (48.1%)
Step 3 Week 36	400/810 (49.4%)	2/6 (33.3%)	9/24 (37.5%)	3/13 (23.1%)	24/42 (57.1%)	27/51 (52.9%)	11/27 (40.7%)
Step 3 Week 48	259/783 (33.1%)	1/5 (20.0%)	6/23 (26.1%)	2/13 (15.4%)	16/40 (40.0%)	17/50 (34.0%)	9/27 (33.3%)
Annual Follow-up							
Yearly visit 1	82/235 (34.9%)	1/3 (33.3%)	5/7 (71.4%)	1/5 (20.0%)	3/6 (50.0%)	2/7 (28.6%)	9/10 (90.0%)
Yearly visit 2	38/106 (35.8%)	1/3 (33.3%)	4/5 (80.0%)	0/5 (0.0%)	0/1 (0.0%)	1/5 (20.0%)	6/7 (85.7%)
Yearly visit 3	9/38 (23.7%)	0/1 (0.0%)	1/2 (50.0%)	0/1 (0.0%)	0/0 (-%)	0/0 (-%)	3/3 (100.0%)
Yearly visit 4	0/5 (0.0%)	0/0 (-%)	0/0 (-%)	0/1 (0.0%)	0/0 (-%)	0/0 (-%)	0/0 (-%)
All visits							
Number of visits completed	47161/65983 (71.5%)	675/963 (70.1%)	1595/2231 (71.5%)	488/762 (64.0%)	2029/2650 (76.6%)	2392/3191 (75.0%)	1545/2282 (67.7%)

¹ "Visit Completion" is defined as the number (and %) of participants who completed the visit among the participants who are expected according to the protocol schedule, plus any participants who have completed the visit even though their visit window has not yet closed. "Expected according to the protocol schedule" in step 2 refers to all participants who are active (Alive, HIV uninfected, have not permanently discontinued randomized study product, and not terminated from study) at the time of the visit and the visit window has closed. Participants who transitioned early to step 3 or annual follow-up are "expected" if they are alive, HIV un-infected and not terminated from the study at the time of the visit and the visit window has closed.

² Inappropriately enrolled participants and participants with invalid ID due to duplicate screening or enrollment are excluded.

HPTN 083 – A Phase 2b/3 Double Blind Safety and Efficacy Study of Injectable Cabotegravir Compared to Daily Oral Tenofovir Disoproxil Fumarate/ Emtricitabine (TDF/FTC), For Pre-Exposure Prophylaxis in HIV-Uninfected Cisgender Men and Transgender Women who have Sex with Men
LIVE Open Report – March 5, 2026
Visit Cutoff Date: March 5, 2026

Table O7A – Visit Completion by Visit and Site – Region: US ¹

	Chapel Hill	Chicago – AYAR	Chicago – WISH	Cincinnati	Columbus	Decatur	Greensboro
Step 1							
Total participants enrolled ²	68	69	73	79	55	86	58
Week 2	64/67 (95.5%)	68/69 (98.6%)	68/72 (94.4%)	78/79 (98.7%)	53/54 (98.1%)	78/86 (90.7%)	57/58 (98.3%)
Week 4	67/67 (100.0%)	66/67 (98.5%)	64/71 (90.1%)	76/78 (97.4%)	52/53 (98.1%)	83/84 (98.8%)	56/56 (100.0%)
Step 2							
Week 5 (Injection #1)	65/65 (100.0%)	62/62 (100.0%)	61/63 (96.8%)	73/73 (100.0%)	48/48 (100.0%)	79/79 (100.0%)	53/53 (100.0%)
1 week post-injection	65/65 (100.0%)	61/62 (98.4%)	61/63 (96.8%)	72/73 (98.6%)	48/48 (100.0%)	79/79 (100.0%)	53/53 (100.0%)
Week 9 (Injection #2)	65/65 (100.0%)	61/62 (98.4%)	61/63 (96.8%)	69/72 (95.8%)	47/48 (97.9%)	78/79 (98.7%)	53/53 (100.0%)
1 week post-injection	65/65 (100.0%)	60/61 (98.4%)	61/63 (96.8%)	68/72 (94.4%)	47/48 (97.9%)	76/78 (97.4%)	53/53 (100.0%)
Week 17 (Injection #3)	60/60 (100.0%)	58/60 (96.7%)	59/62 (95.2%)	66/71 (93.0%)	47/47 (100.0%)	73/76 (96.1%)	50/53 (94.3%)
2 weeks post-injection	60/60 (100.0%)	56/57 (98.2%)	57/61 (93.4%)	66/70 (94.3%)	47/47 (100.0%)	72/75 (96.0%)	50/50 (100.0%)
Week 25 (Injection #4)	58/60 (96.7%)	55/57 (96.5%)	57/61 (93.4%)	65/68 (95.6%)	45/45 (100.0%)	73/74 (98.6%)	50/50 (100.0%)
2 weeks post-injection	58/59 (98.3%)	52/55 (94.5%)	56/60 (93.3%)	62/68 (91.2%)	45/45 (100.0%)	73/74 (98.6%)	50/50 (100.0%)
Week 33 (Injection #5)	58/59 (98.3%)	53/54 (98.1%)	53/60 (88.3%)	64/66 (97.0%)	45/45 (100.0%)	73/73 (100.0%)	50/50 (100.0%)
2 weeks post-injection	56/58 (96.6%)	52/54 (96.3%)	50/59 (84.7%)	62/66 (93.9%)	45/45 (100.0%)	73/73 (100.0%)	48/48 (100.0%)
Week 41 (Injection #6)	54/56 (96.4%)	52/54 (96.3%)	51/59 (86.4%)	63/66 (95.5%)	44/45 (97.8%)	69/72 (95.8%)	48/48 (100.0%)
2 weeks post-injection	53/55 (96.4%)	52/53 (98.1%)	49/58 (84.5%)	58/66 (87.9%)	44/44 (100.0%)	68/71 (95.8%)	48/48 (100.0%)
Week 49 (Injection #7)	50/53 (94.3%)	51/53 (96.2%)	50/58 (86.2%)	62/66 (93.9%)	43/43 (100.0%)	66/70 (94.3%)	45/48 (93.8%)
2 weeks post-injection	49/52 (94.2%)	51/52 (98.1%)	50/58 (86.2%)	59/64 (92.2%)	42/43 (97.7%)	66/70 (94.3%)	45/46 (97.8%)
Week 57 (Injection #8)	49/51 (96.1%)	52/52 (100.0%)	49/58 (84.5%)	61/63 (96.8%)	42/43 (97.7%)	67/69 (97.1%)	44/46 (95.7%)
2 weeks post-injection	49/51 (96.1%)	52/52 (100.0%)	49/58 (84.5%)	60/62 (96.8%)	42/43 (97.7%)	66/69 (95.7%)	44/46 (95.7%)
Week 65 (Injection #9)	49/51 (96.1%)	51/52 (98.1%)	45/58 (77.6%)	60/61 (98.4%)	41/43 (95.3%)	63/69 (91.3%)	45/46 (97.8%)
2 weeks post-injection	49/50 (98.0%)	51/52 (98.1%)	43/58 (74.1%)	59/60 (98.3%)	40/42 (95.2%)	60/68 (88.2%)	43/45 (95.6%)
Week 73 (Injection #10)	48/50 (96.0%)	50/51 (98.0%)	42/57 (73.7%)	57/59 (96.6%)	39/42 (92.9%)	59/64 (92.2%)	41/44 (93.2%)
2 weeks post-injection	45/49 (91.8%)	50/51 (98.0%)	39/57 (68.4%)	56/58 (96.6%)	36/42 (85.7%)	54/63 (85.7%)	40/43 (93.0%)
Week 81 (Injection #11)	45/48 (93.8%)	50/51 (98.0%)	37/57 (64.9%)	53/58 (91.4%)	34/39 (87.2%)	57/63 (90.5%)	39/43 (90.7%)
2 weeks post-injection	43/48 (89.6%)	50/50 (100.0%)	35/57 (61.4%)	49/58 (84.5%)	31/39 (79.5%)	45/63 (71.4%)	38/43 (88.4%)
Week 89 (Injection #12)	43/48 (89.6%)	50/50 (100.0%)	33/57 (57.9%)	54/57 (94.7%)	33/39 (84.6%)	57/63 (90.5%)	39/43 (90.7%)
2 weeks post-injection	37/47 (78.7%)	48/50 (96.0%)	31/56 (55.4%)	43/56 (76.8%)	29/39 (74.4%)	42/62 (67.7%)	34/42 (81.0%)
Week 97 (Injection #13)	44/47 (93.6%)	50/50 (100.0%)	25/55 (45.5%)	52/55 (94.5%)	33/39 (84.6%)	54/62 (87.1%)	37/42 (88.1%)
2 weeks post-injection	35/47 (74.5%)	44/50 (88.0%)	24/54 (44.4%)	40/55 (72.7%)	25/39 (64.1%)	40/62 (64.5%)	30/40 (75.0%)
Week 105 (Injection #14)	43/47 (91.5%)	48/50 (96.0%)	22/54 (40.7%)	50/55 (90.9%)	29/39 (74.4%)	53/61 (86.9%)	35/39 (89.7%)
2 weeks post-injection	31/47 (66.0%)	42/49 (85.7%)	20/54 (37.0%)	35/54 (64.8%)	19/39 (48.7%)	36/61 (59.0%)	28/39 (71.8%)
Week 113 (Injection #15)	37/46 (80.4%)	46/49 (93.9%)	22/54 (40.7%)	48/54 (88.9%)	31/39 (79.5%)	51/60 (85.0%)	34/39 (87.2%)

¹ "Visit Completion" is defined as the number (and %) of participants who completed the visit among the participants who are expected according to the protocol schedule, plus any participants who have completed the visit even though their visit window has not yet closed. "Expected according to the protocol schedule" in step 2 refers to all participants who are active (Alive, HIV uninfected, have not permanently discontinued randomized study product, and not terminated from study) at the time of the visit and the visit window has closed. Participants who transitioned early to step 3 or annual follow-up are "expected" if they are alive, HIV uninfected and not terminated from the study at the time of the visit and the visit window has closed.

² Inappropriately enrolled participants and participants with invalid ID due to duplicate screening or enrollment are excluded.

HPTN 083 – A Phase 2b/3 Double Blind Safety and Efficacy Study of Injectable Cabotegravir Compared to Daily Oral Tenofovir Disoproxil Fumarate/ Emtricitabine (TDF/FTC), For Pre-Exposure Prophylaxis in HIV-Uninfected Cisgender Men and Transgender Women who have Sex with Men
LIVE Open Report – March 5, 2026
Visit Cutoff Date: March 5, 2026

Table O7A – Visit Completion by Visit and Site – Region: US ¹

	Chapel Hill	Chicago – AYAR	Chicago – WISH	Cincinnati	Columbus	Decatur	Greensboro
2 weeks post-injection	23/45 (51.1%)	37/48 (77.1%)	21/54 (38.9%)	33/53 (62.3%)	14/37 (37.8%)	29/60 (48.3%)	24/37 (64.9%)
Week 121 (Injection #16)	38/44 (86.4%)	45/48 (93.8%)	19/53 (35.8%)	47/52 (90.4%)	30/36 (83.3%)	48/60 (80.0%)	32/37 (86.5%)
2 weeks post-injection	19/43 (44.2%)	34/48 (70.8%)	16/53 (30.2%)	28/50 (56.0%)	13/36 (36.1%)	21/59 (35.6%)	21/37 (56.8%)
Week 129 (Injection #17)	41/43 (95.3%)	45/48 (93.8%)	18/51 (35.3%)	37/50 (74.0%)	30/35 (85.7%)	38/58 (65.5%)	30/36 (83.3%)
2 weeks post-injection	16/43 (37.2%)	32/48 (66.7%)	13/51 (25.5%)	22/49 (44.9%)	10/35 (28.6%)	19/58 (32.8%)	21/36 (58.3%)
Week 137 (Injection #18)	38/43 (88.4%)	43/48 (89.6%)	13/48 (27.1%)	33/49 (67.3%)	24/35 (68.6%)	32/58 (55.2%)	30/36 (83.3%)
2 weeks post-injection	12/38 (31.6%)	25/44 (56.8%)	5/48 (10.4%)	17/49 (34.7%)	5/34 (14.7%)	16/56 (28.6%)	16/35 (45.7%)
Week 145 (Injection #19)	30/38 (78.9%)	37/44 (84.1%)	3/48 (6.3%)	29/49 (59.2%)	22/32 (68.8%)	31/56 (55.4%)	25/34 (73.5%)
2 weeks post-injection	10/38 (26.3%)	21/44 (47.7%)	0/47 (0.0%)	14/48 (29.2%)	2/32 (6.3%)	11/55 (20.0%)	14/32 (43.8%)
Week 153 (Injection #20)	29/36 (80.6%)	36/44 (81.8%)	2/44 (4.5%)	28/48 (58.3%)	21/30 (70.0%)	28/55 (50.9%)	23/31 (74.2%)
2 weeks post-injection	2/34 (5.9%)	1/43 (2.3%)	0/37 (0.0%)	0/45 (0.0%)	0/29 (0.0%)	0/55 (0.0%)	0/30 (0.0%)
Week 161 (Injection #21)	0/33 (0.0%)	0/43 (0.0%)	0/37 (0.0%)	0/45 (0.0%)	0/29 (0.0%)	0/55 (0.0%)	0/30 (0.0%)
2 weeks post-injection	0/33 (0.0%)	0/43 (0.0%)	0/37 (0.0%)	0/45 (0.0%)	0/29 (0.0%)	0/55 (0.0%)	0/30 (0.0%)
Step 3 (Open-label TDF/FTC)							
Step 3 Week 12	39/46 (84.8%)	35/40 (87.5%)	4/21 (19.0%)	34/47 (72.3%)	23/34 (67.6%)	30/37 (81.1%)	24/31 (77.4%)
Step 3 Week 24	30/45 (66.7%)	30/40 (75.0%)	6/19 (31.6%)	25/44 (56.8%)	18/32 (56.3%)	23/36 (63.9%)	23/30 (76.7%)
Step 3 Week 36	27/44 (61.4%)	22/40 (55.0%)	2/13 (15.4%)	20/42 (47.6%)	14/30 (46.7%)	17/35 (48.6%)	19/29 (65.5%)
Step 3 Week 48	20/43 (46.5%)	12/38 (31.6%)	3/13 (23.1%)	14/41 (34.1%)	10/29 (34.5%)	8/33 (24.2%)	16/28 (57.1%)
Annual Follow-up							
Yearly visit 1	8/16 (50.0%)	3/13 (23.1%)	2/3 (66.7%)	7/14 (50.0%)	0/1 (0.0%)	0/4 (0.0%)	4/15 (26.7%)
Yearly visit 2	2/6 (33.3%)	0/4 (0.0%)	0/1 (0.0%)	3/5 (60.0%)	0/0 (-%)	0/0 (-%)	1/4 (25.0%)
Yearly visit 3	0/2 (0.0%)	0/0 (-%)	0/0 (-%)	0/1 (0.0%)	0/0 (-%)	0/0 (-%)	0/1 (0.0%)
Yearly visit 4	0/0 (-%)	0/0 (-%)	0/0 (-%)	0/0 (-%)	0/0 (-%)	0/0 (-%)	0/0 (-%)
All visits							
Number of visits completed	2056/2682 (76.7%)	2175/2790 (78.0%)	1624/2808 (57.8%)	2320/3168 (73.2%)	1543/2144 (72.0%)	2424/3477 (69.7%)	1764/2277 (77.5%)

¹ "Visit Completion" is defined as the number (and %) of participants who completed the visit among the participants who are expected according to the protocol schedule, plus any participants who have completed the visit even though their visit window has not yet closed. "Expected according to the protocol schedule" in step 2 refers to all participants who are active (Alive, HIV uninfected, have not permanently discontinued randomized study product, and not terminated from study) at the time of the visit and the visit window has closed. Participants who transitioned early to step 3 or annual follow-up are "expected" if they are alive, HIV un-infected and not terminated from the study at the time of the visit and the visit window has closed.

² Inappropriately enrolled participants and participants with invalid ID due to duplicate screening or enrollment are excluded.

HPTN 083 – A Phase 2b/3 Double Blind Safety and Efficacy Study of Injectable Cabotegravir Compared to Daily Oral Tenofovir Disoproxil Fumarate/ Emtricitabine (TDF/FTC), For Pre-Exposure Prophylaxis in HIV-Uninfected Cisgender Men and Transgender Women who have Sex with Men
LIVE Open Report – March 5, 2026
Visit Cutoff Date: March 5, 2026

Table O7A – Visit Completion by Visit and Site – Region: US ¹

	Harlem	Houston	Los Angeles – UCLA Care	Los Angeles – UCLA Vine	Memphis	New Orleans	New York – Blood Center
Step 1							
Total participants enrolled ²	58	60	65	70	93	53	67
Week 2	55/58 (94.8%)	58/59 (98.3%)	63/65 (96.9%)	65/67 (97.0%)	88/93 (94.6%)	53/53 (100.0%)	63/66 (95.5%)
Week 4	58/58 (100.0%)	58/59 (98.3%)	63/64 (98.4%)	62/62 (100.0%)	90/93 (96.8%)	50/51 (98.0%)	59/63 (93.7%)
Step 2							
Week 5 (Injection #1)	52/52 (100.0%)	55/55 (100.0%)	62/62 (100.0%)	57/57 (100.0%)	83/83 (100.0%)	47/47 (100.0%)	57/57 (100.0%)
1 week post-injection	52/52 (100.0%)	55/55 (100.0%)	61/62 (98.4%)	57/57 (100.0%)	82/82 (100.0%)	47/47 (100.0%)	57/57 (100.0%)
Week 9 (Injection #2)	50/51 (98.0%)	51/53 (96.2%)	61/61 (100.0%)	56/57 (98.2%)	80/82 (97.6%)	46/46 (100.0%)	56/57 (98.2%)
1 week post-injection	50/51 (98.0%)	50/51 (98.0%)	60/61 (98.4%)	56/56 (100.0%)	80/82 (97.6%)	46/46 (100.0%)	55/56 (98.2%)
Week 17 (Injection #3)	50/50 (100.0%)	45/51 (88.2%)	59/59 (100.0%)	50/52 (96.2%)	78/81 (96.3%)	42/45 (93.3%)	55/55 (100.0%)
2 weeks post-injection	50/50 (100.0%)	45/50 (90.0%)	58/58 (100.0%)	49/50 (98.0%)	77/79 (97.5%)	42/45 (93.3%)	54/54 (100.0%)
Week 25 (Injection #4)	50/50 (100.0%)	44/49 (89.8%)	54/57 (94.7%)	49/50 (98.0%)	75/77 (97.4%)	41/45 (91.1%)	51/53 (96.2%)
2 weeks post-injection	50/50 (100.0%)	44/49 (89.8%)	54/56 (96.4%)	47/48 (97.9%)	73/76 (96.1%)	41/45 (91.1%)	51/52 (98.1%)
Week 33 (Injection #5)	49/50 (98.0%)	45/49 (91.8%)	54/56 (96.4%)	45/48 (93.8%)	70/76 (92.1%)	39/44 (88.6%)	49/51 (96.1%)
2 weeks post-injection	49/50 (98.0%)	45/49 (91.8%)	53/55 (96.4%)	45/48 (93.8%)	69/76 (90.8%)	39/44 (88.6%)	49/51 (96.1%)
Week 41 (Injection #6)	49/50 (98.0%)	44/49 (89.8%)	54/55 (98.2%)	46/48 (95.8%)	66/75 (88.0%)	40/44 (90.9%)	46/51 (90.2%)
2 weeks post-injection	48/50 (96.0%)	43/49 (87.8%)	54/55 (98.2%)	46/48 (95.8%)	66/73 (90.4%)	40/44 (90.9%)	46/49 (93.9%)
Week 49 (Injection #7)	47/49 (95.9%)	43/49 (87.8%)	54/54 (100.0%)	46/48 (95.8%)	66/72 (91.7%)	39/44 (88.6%)	46/49 (93.9%)
2 weeks post-injection	46/49 (93.9%)	39/48 (81.3%)	54/54 (100.0%)	46/48 (95.8%)	65/70 (92.9%)	38/43 (88.4%)	46/49 (93.9%)
Week 57 (Injection #8)	39/48 (81.3%)	39/47 (83.0%)	51/54 (94.4%)	45/47 (95.7%)	63/69 (91.3%)	38/43 (88.4%)	45/49 (91.8%)
2 weeks post-injection	39/48 (81.3%)	39/47 (83.0%)	49/51 (96.1%)	45/47 (95.7%)	60/69 (87.0%)	37/43 (86.0%)	43/48 (89.6%)
Week 65 (Injection #9)	35/47 (74.5%)	41/47 (87.2%)	51/51 (100.0%)	45/47 (95.7%)	59/68 (86.8%)	33/42 (78.6%)	43/48 (89.6%)
2 weeks post-injection	33/47 (70.2%)	40/47 (85.1%)	50/51 (98.0%)	45/47 (95.7%)	57/64 (89.1%)	33/42 (78.6%)	43/48 (89.6%)
Week 73 (Injection #10)	37/46 (80.4%)	38/47 (80.9%)	50/51 (98.0%)	45/47 (95.7%)	56/64 (87.5%)	34/40 (85.0%)	41/48 (85.4%)
2 weeks post-injection	30/45 (66.7%)	34/47 (72.3%)	46/50 (92.0%)	45/47 (95.7%)	52/63 (82.5%)	33/40 (82.5%)	40/48 (83.3%)
Week 81 (Injection #11)	38/44 (86.4%)	40/47 (85.1%)	49/50 (98.0%)	44/46 (95.7%)	54/63 (85.7%)	31/40 (77.5%)	41/48 (85.4%)
2 weeks post-injection	29/44 (65.9%)	32/47 (68.1%)	44/50 (88.0%)	40/46 (87.0%)	50/63 (79.4%)	30/40 (75.0%)	38/47 (80.9%)
Week 89 (Injection #12)	36/44 (81.8%)	37/46 (80.4%)	50/50 (100.0%)	43/46 (93.5%)	52/63 (82.5%)	31/39 (79.5%)	40/47 (85.1%)
2 weeks post-injection	25/44 (56.8%)	28/46 (60.9%)	40/50 (80.0%)	38/46 (82.6%)	45/62 (72.6%)	26/37 (70.3%)	33/46 (71.7%)
Week 97 (Injection #13)	38/44 (86.4%)	38/46 (82.6%)	48/49 (98.0%)	42/46 (91.3%)	50/60 (83.3%)	33/37 (89.2%)	36/44 (81.8%)
2 weeks post-injection	21/44 (47.7%)	26/44 (59.1%)	38/49 (77.6%)	30/46 (65.2%)	44/60 (73.3%)	22/34 (64.7%)	25/44 (56.8%)
Week 105 (Injection #14)	36/44 (81.8%)	37/43 (86.0%)	46/49 (93.9%)	42/46 (91.3%)	47/60 (78.3%)	30/34 (88.2%)	35/44 (79.5%)

¹ "Visit Completion" is defined as the number (and %) of participants who completed the visit among the participants who are expected according to the protocol schedule, plus any participants who have completed the visit even though their visit window has not yet closed. "Expected according to the protocol schedule" in step 2 refers to all participants who are active (Alive, HIV uninfected, have not permanently discontinued randomized study product, and not terminated from study) at the time of the visit and the visit window has closed. Participants who transitioned early to step 3 or annual follow-up are "expected" if they are alive, HIV uninfected and not terminated from the study at the time of the visit and the visit window has closed.

² Inappropriately enrolled participants and participants with invalid ID due to duplicate screening or enrollment are excluded.

HPTN 083 – A Phase 2b/3 Double Blind Safety and Efficacy Study of Injectable Cabotegravir Compared to Daily Oral Tenofovir Disoproxil Fumarate/ Emtricitabine (TDF/FTC), For Pre-Exposure Prophylaxis in HIV-Uninfected Cisgender Men and Transgender Women who have Sex with Men
LIVE Open Report – March 5, 2026
Visit Cutoff Date: March 5, 2026

Table O7A – Visit Completion by Visit and Site – Region: US ¹

	Harlem	Houston	Los Angeles – UCLA Care	Los Angeles – UCLA Vine	Memphis	New Orleans	New York – Blood Center
2 weeks post-injection	21/43 (48.8%)	21/42 (50.0%)	33/49 (67.3%)	28/44 (63.6%)	37/59 (62.7%)	20/33 (60.6%)	23/44 (52.3%)
Week 113 (Injection #15)	30/43 (69.8%)	33/42 (78.6%)	44/49 (89.8%)	40/44 (90.9%)	45/59 (76.3%)	29/32 (90.6%)	35/44 (79.5%)
2 weeks post-injection	15/42 (35.7%)	15/40 (37.5%)	30/49 (61.2%)	23/44 (52.3%)	36/58 (62.1%)	16/31 (51.6%)	19/43 (44.2%)
Week 121 (Injection #16)	28/42 (66.7%)	33/40 (82.5%)	43/49 (87.8%)	40/44 (90.9%)	41/57 (71.9%)	29/31 (93.5%)	32/42 (76.2%)
2 weeks post-injection	14/42 (33.3%)	10/39 (25.6%)	26/49 (53.1%)	22/44 (50.0%)	30/57 (52.6%)	15/30 (50.0%)	12/42 (28.6%)
Week 129 (Injection #17)	23/42 (54.8%)	34/39 (87.2%)	41/49 (83.7%)	40/44 (90.9%)	40/56 (71.4%)	28/30 (93.3%)	29/42 (69.0%)
2 weeks post-injection	10/41 (24.4%)	7/37 (18.9%)	25/49 (51.0%)	17/44 (38.6%)	28/56 (50.0%)	12/30 (40.0%)	11/42 (26.2%)
Week 137 (Injection #18)	19/41 (46.3%)	28/37 (75.7%)	40/49 (81.6%)	37/43 (86.0%)	41/55 (74.5%)	27/30 (90.0%)	29/41 (70.7%)
2 weeks post-injection	9/41 (22.0%)	5/37 (13.5%)	21/48 (43.8%)	11/42 (26.2%)	26/54 (48.1%)	8/30 (26.7%)	8/41 (19.5%)
Week 145 (Injection #19)	15/40 (37.5%)	26/37 (70.3%)	34/47 (72.3%)	28/40 (70.0%)	41/54 (75.9%)	24/30 (80.0%)	25/41 (61.0%)
2 weeks post-injection	4/39 (10.3%)	2/37 (5.4%)	14/47 (29.8%)	7/40 (17.5%)	18/54 (33.3%)	5/30 (16.7%)	7/41 (17.1%)
Week 153 (Injection #20)	14/38 (36.8%)	21/37 (56.8%)	31/47 (66.0%)	24/40 (60.0%)	36/54 (66.7%)	22/30 (73.3%)	19/41 (46.3%)
2 weeks post-injection	0/38 (0.0%)	0/34 (0.0%)	1/47 (2.1%)	0/37 (0.0%)	8/50 (16.0%)	0/29 (0.0%)	0/39 (0.0%)
Week 161 (Injection #21)	0/38 (0.0%)	0/34 (0.0%)	0/47 (0.0%)	0/37 (0.0%)	3/50 (6.0%)	0/29 (0.0%)	0/39 (0.0%)
2 weeks post-injection	0/38 (0.0%)	0/34 (0.0%)	0/47 (0.0%)	0/37 (0.0%)	0/50 (0.0%)	0/29 (0.0%)	0/39 (0.0%)
Step 3 (Open-label TDF/FTC)							
Step 3 Week 12	21/28 (75.0%)	21/25 (84.0%)	29/34 (85.3%)	24/30 (80.0%)	40/49 (81.6%)	20/28 (71.4%)	13/18 (72.2%)
Step 3 Week 24	20/28 (71.4%)	15/25 (60.0%)	28/34 (82.4%)	19/30 (63.3%)	29/45 (64.4%)	20/28 (71.4%)	7/17 (41.2%)
Step 3 Week 36	13/27 (48.1%)	8/23 (34.8%)	21/32 (65.6%)	13/30 (43.3%)	24/44 (54.5%)	16/28 (57.1%)	6/17 (35.3%)
Step 3 Week 48	10/27 (37.0%)	4/23 (17.4%)	14/32 (43.8%)	5/27 (18.5%)	5/41 (12.2%)	10/25 (40.0%)	4/17 (23.5%)
Annual Follow-up							
Yearly visit 1	1/2 (50.0%)	2/7 (28.6%)	0/9 (0.0%)	10/11 (90.9%)	3/13 (23.1%)	3/8 (37.5%)	0/7 (0.0%)
Yearly visit 2	1/1 (100.0%)	1/4 (25.0%)	0/0 (-%)	7/10 (70.0%)	1/2 (50.0%)	3/3 (100.0%)	0/3 (0.0%)
Yearly visit 3	0/0 (-%)	0/1 (0.0%)	0/0 (-%)	2/3 (66.7%)	0/1 (0.0%)	1/1 (100.0%)	0/2 (0.0%)
Yearly visit 4	0/0 (-%)	0/0 (-%)	0/0 (-%)	0/0 (-%)	0/0 (-%)	0/0 (-%)	0/0 (-%)
All visits							
Number of visits completed	1570/2419 (64.9%)	1582/2366 (66.9%)	2073/2802 (74.0%)	1843/2510 (73.4%)	2528/3515 (71.9%)	1465/2049 (71.5%)	1691/2484 (68.1%)

¹ "Visit Completion" is defined as the number (and %) of participants who completed the visit among the participants who are expected according to the protocol schedule, plus any participants who have completed the visit even though their visit window has not yet closed. "Expected according to the protocol schedule" in step 2 refers to all participants who are active (Alive, HIV uninfected, have not permanently discontinued randomized study product, and not terminated from study) at the time of the visit and the visit window has closed. Participants who transitioned early to step 3 or annual follow-up are "expected" if they are alive, HIV uninfected and not terminated from the study at the time of the visit and the visit window has closed.

² Inappropriately enrolled participants and participants with invalid ID due to duplicate screening or enrollment are excluded.

HPTN 083 – A Phase 2b/3 Double Blind Safety and Efficacy Study of Injectable Cabotegravir Compared to Daily Oral Tenofovir Disoproxil Fumarate/ Emtricitabine (TDF/FTC), For Pre-Exposure Prophylaxis in HIV-Uninfected Cisgender Men and Transgender Women who have Sex with Men
LIVE Open Report – March 5, 2026
Visit Cutoff Date: March 5, 2026

Table O7A – Visit Completion by Visit and Site – Region: US ¹

	New York – Weill Cornell Chelsea	Newark	Oakland	Philadelphia	San Francisco	St. Louis	Washington, DC
Step 1							
Total participants enrolled ²	65	66	40	88	26	65	61
Week 2	61/65 (93.8%)	65/65 (100.0%)	38/38 (100.0%)	86/88 (97.7%)	26/26 (100.0%)	63/64 (98.4%)	61/61 (100.0%)
Week 4	62/62 (100.0%)	64/64 (100.0%)	36/36 (100.0%)	82/83 (98.8%)	26/26 (100.0%)	63/64 (98.4%)	60/61 (98.4%)
Step 2							
Week 5 (Injection #1)	60/60 (100.0%)	56/56 (100.0%)	36/36 (100.0%)	77/77 (100.0%)	26/26 (100.0%)	62/62 (100.0%)	58/58 (100.0%)
1 week post-injection	60/60 (100.0%)	56/56 (100.0%)	36/36 (100.0%)	77/77 (100.0%)	26/26 (100.0%)	62/62 (100.0%)	58/58 (100.0%)
Week 9 (Injection #2)	58/58 (100.0%)	55/56 (98.2%)	35/35 (100.0%)	77/77 (100.0%)	25/26 (96.2%)	62/62 (100.0%)	57/57 (100.0%)
1 week post-injection	58/58 (100.0%)	55/56 (98.2%)	35/35 (100.0%)	77/77 (100.0%)	24/26 (92.3%)	59/59 (100.0%)	57/57 (100.0%)
Week 17 (Injection #3)	55/55 (100.0%)	53/55 (96.4%)	33/33 (100.0%)	73/75 (97.3%)	23/25 (92.0%)	59/59 (100.0%)	55/55 (100.0%)
2 weeks post-injection	55/55 (100.0%)	53/55 (96.4%)	33/33 (100.0%)	73/75 (97.3%)	23/25 (92.0%)	56/57 (98.2%)	54/54 (100.0%)
Week 25 (Injection #4)	53/54 (98.1%)	52/54 (96.3%)	32/32 (100.0%)	73/73 (100.0%)	21/24 (87.5%)	55/56 (98.2%)	54/54 (100.0%)
2 weeks post-injection	51/53 (96.2%)	52/54 (96.3%)	32/32 (100.0%)	72/73 (98.6%)	21/24 (87.5%)	54/54 (100.0%)	54/54 (100.0%)
Week 33 (Injection #5)	51/52 (98.1%)	53/54 (98.1%)	32/32 (100.0%)	73/73 (100.0%)	21/24 (87.5%)	47/51 (92.2%)	54/54 (100.0%)
2 weeks post-injection	51/52 (98.1%)	53/54 (98.1%)	32/32 (100.0%)	73/73 (100.0%)	21/24 (87.5%)	47/50 (94.0%)	54/54 (100.0%)
Week 41 (Injection #6)	49/51 (96.1%)	50/53 (94.3%)	31/32 (96.9%)	71/72 (98.6%)	22/23 (95.7%)	46/50 (92.0%)	54/54 (100.0%)
2 weeks post-injection	47/50 (94.0%)	48/53 (90.6%)	30/31 (96.8%)	70/71 (98.6%)	22/23 (95.7%)	46/49 (93.9%)	54/54 (100.0%)
Week 49 (Injection #7)	44/48 (91.7%)	49/53 (92.5%)	28/31 (90.3%)	68/69 (98.6%)	22/22 (100.0%)	46/48 (95.8%)	53/54 (98.1%)
2 weeks post-injection	43/48 (89.6%)	49/53 (92.5%)	28/31 (90.3%)	68/69 (98.6%)	22/22 (100.0%)	46/48 (95.8%)	53/54 (98.1%)
Week 57 (Injection #8)	41/48 (85.4%)	49/52 (94.2%)	28/29 (96.6%)	67/68 (98.5%)	22/22 (100.0%)	45/47 (95.7%)	53/54 (98.1%)
2 weeks post-injection	39/48 (81.3%)	49/52 (94.2%)	28/29 (96.6%)	66/67 (98.5%)	22/22 (100.0%)	45/45 (100.0%)	51/52 (98.1%)
Week 65 (Injection #9)	36/47 (76.6%)	46/52 (88.5%)	28/29 (96.6%)	65/66 (98.5%)	22/22 (100.0%)	45/45 (100.0%)	48/50 (96.0%)
2 weeks post-injection	36/47 (76.6%)	43/51 (84.3%)	28/29 (96.6%)	62/66 (93.9%)	21/21 (100.0%)	45/45 (100.0%)	48/49 (98.0%)
Week 73 (Injection #10)	36/47 (76.6%)	47/51 (92.2%)	26/28 (92.9%)	57/64 (89.1%)	20/21 (95.2%)	44/44 (100.0%)	48/49 (98.0%)
2 weeks post-injection	34/47 (72.3%)	40/50 (80.0%)	26/28 (92.9%)	54/64 (84.4%)	20/21 (95.2%)	44/44 (100.0%)	47/49 (95.9%)
Week 81 (Injection #11)	38/47 (80.9%)	45/49 (91.8%)	26/28 (92.9%)	59/64 (92.2%)	20/21 (95.2%)	42/44 (95.5%)	48/49 (98.0%)
2 weeks post-injection	33/47 (70.2%)	37/48 (77.1%)	24/28 (85.7%)	49/63 (77.8%)	20/21 (95.2%)	42/44 (95.5%)	43/49 (87.8%)
Week 89 (Injection #12)	38/47 (80.9%)	42/48 (87.5%)	25/27 (92.6%)	58/63 (92.1%)	20/21 (95.2%)	41/44 (93.2%)	45/49 (91.8%)
2 weeks post-injection	29/47 (61.7%)	29/48 (60.4%)	21/26 (80.8%)	47/63 (74.6%)	20/21 (95.2%)	40/43 (93.0%)	34/49 (69.4%)
Week 97 (Injection #13)	34/46 (73.9%)	40/48 (83.3%)	24/25 (96.0%)	56/61 (91.8%)	21/21 (100.0%)	39/42 (92.9%)	44/46 (95.7%)
2 weeks post-injection	27/46 (58.7%)	24/48 (50.0%)	20/25 (80.0%)	39/60 (65.0%)	21/21 (100.0%)	39/42 (92.9%)	31/45 (68.9%)
Week 105 (Injection #14)	32/45 (71.1%)	40/48 (83.3%)	22/24 (91.7%)	54/58 (93.1%)	20/21 (95.2%)	39/41 (95.1%)	40/44 (90.9%)
2 weeks post-injection	23/45 (51.1%)	17/47 (36.2%)	17/23 (73.9%)	32/58 (55.2%)	20/21 (95.2%)	39/41 (95.1%)	23/43 (53.5%)

¹ "Visit Completion" is defined as the number (and %) of participants who completed the visit among the participants who are expected according to the protocol schedule, plus any participants who have completed the visit even though their visit window has not yet closed. "Expected according to the protocol schedule" in step 2 refers to all participants who are active (Alive, HIV uninfected, have not permanently discontinued randomized study product, and not terminated from study) at the time of the visit and the visit window has closed. Participants who transitioned early to step 3 or annual follow-up are "expected" if they are alive, HIV un-infected and not terminated from the study at the time of the visit and the visit window has closed.

² Inappropriately enrolled participants and participants with invalid ID due to duplicate screening or enrollment are excluded.

HPTN 083 – A Phase 2b/3 Double Blind Safety and Efficacy Study of Injectable Cabotegravir Compared to Daily Oral Tenofovir Disoproxil Fumarate/ Emtricitabine (TDF/FTC), For Pre-Exposure Prophylaxis in HIV-Uninfected Cisgender Men and Transgender Women who have Sex with Men
LIVE Open Report – March 5, 2026
Visit Cutoff Date: March 5, 2026

Table O7A – Visit Completion by Visit and Site – Region: US ¹

	New York – Weill Cornell Chelsea	Newark	Oakland	Philadelphia	San Francisco	St. Louis	Washington, DC
Week 113 (Injection #15)	25/44 (56.8%)	38/46 (82.6%)	19/23 (82.6%)	52/58 (89.7%)	18/21 (85.7%)	40/41 (97.6%)	40/42 (95.2%)
2 weeks post-injection	17/44 (38.6%)	13/46 (28.3%)	14/23 (60.9%)	30/58 (51.7%)	14/20 (70.0%)	39/41 (95.1%)	24/42 (57.1%)
Week 121 (Injection #16)	24/44 (54.5%)	37/46 (80.4%)	19/23 (82.6%)	51/58 (87.9%)	16/20 (80.0%)	39/41 (95.1%)	38/41 (92.7%)
2 weeks post-injection	14/43 (32.6%)	11/45 (24.4%)	10/23 (43.5%)	28/58 (48.3%)	10/20 (50.0%)	38/40 (95.0%)	16/41 (39.0%)
Week 129 (Injection #17)	23/42 (54.8%)	35/45 (77.8%)	16/23 (69.6%)	46/58 (79.3%)	17/20 (85.0%)	32/40 (80.0%)	36/40 (90.0%)
2 weeks post-injection	11/42 (26.2%)	7/45 (15.6%)	7/22 (31.8%)	23/58 (39.7%)	7/20 (35.0%)	29/39 (74.4%)	12/38 (31.6%)
Week 137 (Injection #18)	16/42 (38.1%)	32/45 (71.1%)	15/22 (68.2%)	42/58 (72.4%)	16/20 (80.0%)	26/38 (68.4%)	31/38 (81.6%)
2 weeks post-injection	5/41 (12.2%)	2/44 (4.5%)	4/22 (18.2%)	18/57 (31.6%)	4/20 (20.0%)	22/37 (59.5%)	11/38 (28.9%)
Week 145 (Injection #19)	14/40 (35.0%)	27/44 (61.4%)	14/22 (63.6%)	39/56 (69.6%)	13/20 (65.0%)	16/36 (44.4%)	26/38 (68.4%)
2 weeks post-injection	2/39 (5.1%)	1/44 (2.3%)	0/22 (0.0%)	11/55 (20.0%)	1/20 (5.0%)	15/36 (41.7%)	9/38 (23.7%)
Week 153 (Injection #20)	10/39 (25.6%)	22/44 (50.0%)	11/22 (50.0%)	30/55 (54.5%)	18/20 (90.0%)	26/36 (72.2%)	22/35 (62.9%)
2 weeks post-injection	0/36 (0.0%)	0/44 (0.0%)	0/21 (0.0%)	0/52 (0.0%)	0/18 (0.0%)	0/35 (0.0%)	0/35 (0.0%)
Week 161 (Injection #21)	0/36 (0.0%)	0/44 (0.0%)	0/21 (0.0%)	0/52 (0.0%)	0/18 (0.0%)	0/35 (0.0%)	0/35 (0.0%)
2 weeks post-injection	0/36 (0.0%)	0/44 (0.0%)	0/21 (0.0%)	0/52 (0.0%)	0/18 (0.0%)	0/35 (0.0%)	0/35 (0.0%)
Step 3 (Open-label TDF/FTC)							
Step 3 Week 12	18/34 (52.9%)	22/30 (73.3%)	15/17 (88.2%)	33/40 (82.5%)	21/21 (100.0%)	44/51 (86.3%)	29/33 (87.9%)
Step 3 Week 24	19/32 (59.4%)	13/30 (43.3%)	12/17 (70.6%)	29/39 (74.4%)	17/20 (85.0%)	41/50 (82.0%)	21/33 (63.6%)
Step 3 Week 36	12/30 (40.0%)	8/30 (26.7%)	4/17 (23.5%)	21/35 (60.0%)	11/20 (55.0%)	30/50 (60.0%)	16/31 (51.6%)
Step 3 Week 48	11/29 (37.9%)	5/28 (17.9%)	3/17 (17.6%)	15/34 (44.1%)	4/20 (20.0%)	21/50 (42.0%)	14/30 (46.7%)
Annual Follow-up							
Yearly visit 1	1/5 (20.0%)	7/11 (63.6%)	2/6 (33.3%)	4/8 (50.0%)	0/3 (0.0%)	1/31 (3.2%)	3/10 (30.0%)
Yearly visit 2	0/3 (0.0%)	5/10 (50.0%)	0/4 (0.0%)	1/2 (50.0%)	0/1 (0.0%)	0/15 (0.0%)	1/2 (50.0%)
Yearly visit 3	0/1 (0.0%)	1/4 (25.0%)	0/1 (0.0%)	1/1 (100.0%)	0/0 (-%)	0/11 (0.0%)	0/1 (0.0%)
Yearly visit 4	0/0 (-%)	0/0 (-%)	0/1 (0.0%)	0/0 (-%)	0/0 (-%)	0/3 (0.0%)	0/0 (-%)
All visits							
Number of visits completed	1630/2527 (64.5%)	1765/2684 (65.8%)	1079/1473 (73.3%)	2526/3440 (73.4%)	876/1186 (73.9%)	1998/2584 (77.3%)	1905/2519 (75.6%)

¹ "Visit Completion" is defined as the number (and %) of participants who completed the visit among the participants who are expected according to the protocol schedule, plus any participants who have completed the visit even though their visit window has not yet closed. "Expected according to the protocol schedule" in step 2 refers to all participants who are active (Alive, HIV uninfected, have not permanently discontinued randomized study product, and not terminated from study) at the time of the visit and the visit window has closed. Participants who transitioned early to step 3 or annual follow-up are "expected" if they are alive, HIV uninfected and not terminated from the study at the time of the visit and the visit window has closed.

² Inappropriately enrolled participants and participants with invalid ID due to duplicate screening or enrollment are excluded.

HPTN 083 – A Phase 2b/3 Double Blind Safety and Efficacy Study of Injectable Cabotegravir Compared to Daily Oral Tenofovir Disoproxil Fumarate/ Emtricitabine (TDF/FTC), For Pre-Exposure Prophylaxis in HIV-Uninfected Cisgender Men and Transgender Women who have Sex with Men
LIVE Open Report – March 5, 2026
Visit Cutoff Date: March 5, 2026

Table O7B – Visit Completion by Visit and Site – Region: Latin America ¹

	Overall	Buenos Aires – Fundacion Huesped	Buenos Aires – Hospital JM Ramos Mejia	Iquitos	Lima – Barranco	Lima – CITBM	Lima – San Miguel
Step 1							
Total participants enrolled ²	1964	199	138	177	176	152	150
Week 2	1881/1948 (96.6%)	195/199 (98.0%)	134/138 (97.1%)	170/177 (96.0%)	166/175 (94.9%)	141/144 (97.9%)	143/149 (96.0%)
Week 4	1885/1920 (98.2%)	197/198 (99.5%)	136/136 (100.0%)	168/176 (95.5%)	168/173 (97.1%)	134/136 (98.5%)	139/146 (95.2%)
Step 2							
Week 5 (Injection #1)	1815/1821 (99.7%)	191/191 (100.0%)	134/134 (100.0%)	165/166 (99.4%)	157/157 (100.0%)	126/126 (100.0%)	128/128 (100.0%)
1 week post-injection	1803/1820 (99.1%)	190/191 (99.5%)	134/134 (100.0%)	165/166 (99.4%)	157/157 (100.0%)	124/125 (99.2%)	127/128 (99.2%)
Week 9 (Injection #2)	1745/1808 (96.5%)	188/190 (98.9%)	131/133 (98.5%)	157/166 (94.6%)	148/154 (96.1%)	116/124 (93.5%)	121/126 (96.0%)
1 week post-injection	1725/1799 (95.9%)	185/189 (97.9%)	131/133 (98.5%)	157/166 (94.6%)	148/152 (97.4%)	116/124 (93.5%)	121/126 (96.0%)
Week 17 (Injection #3)	1683/1776 (94.8%)	182/187 (97.3%)	130/133 (97.7%)	153/165 (92.7%)	146/149 (98.0%)	109/117 (93.2%)	118/123 (95.9%)
2 weeks post-injection	1648/1760 (93.6%)	170/186 (91.4%)	130/132 (98.5%)	150/163 (92.0%)	146/149 (98.0%)	105/114 (92.1%)	115/119 (96.6%)
Week 25 (Injection #4)	1613/1743 (92.5%)	177/183 (96.7%)	130/132 (98.5%)	149/161 (92.5%)	144/149 (96.6%)	84/112 (75.0%)	106/116 (91.4%)
2 weeks post-injection	1569/1728 (90.8%)	166/183 (90.7%)	129/131 (98.5%)	148/161 (91.9%)	144/148 (97.3%)	75/111 (67.6%)	101/112 (90.2%)
Week 33 (Injection #5)	1562/1709 (91.4%)	174/182 (95.6%)	128/130 (98.5%)	143/160 (89.4%)	135/148 (91.2%)	84/106 (79.2%)	98/112 (87.5%)
2 weeks post-injection	1448/1699 (85.2%)	160/182 (87.9%)	119/128 (93.0%)	139/160 (86.9%)	132/145 (91.0%)	54/103 (52.4%)	90/112 (80.4%)
Week 41 (Injection #6)	1496/1689 (88.6%)	174/182 (95.6%)	123/128 (96.1%)	134/159 (84.3%)	123/145 (84.8%)	79/100 (79.0%)	81/110 (73.6%)
2 weeks post-injection	1220/1674 (72.9%)	149/181 (82.3%)	101/126 (80.2%)	128/159 (80.5%)	114/143 (79.7%)	30/96 (31.3%)	66/107 (61.7%)
Week 49 (Injection #7)	1402/1657 (84.6%)	168/177 (94.9%)	121/126 (96.0%)	118/156 (75.6%)	102/140 (72.9%)	69/95 (72.6%)	80/106 (75.5%)
2 weeks post-injection	984/1645 (59.8%)	122/177 (68.9%)	85/126 (67.5%)	114/155 (73.5%)	91/137 (66.4%)	20/93 (21.5%)	52/104 (50.0%)
Week 57 (Injection #8)	1434/1635 (87.7%)	168/176 (95.5%)	118/125 (94.4%)	116/155 (74.8%)	102/135 (75.6%)	83/91 (91.2%)	88/103 (85.4%)
2 weeks post-injection	854/1618 (52.8%)	98/175 (56.0%)	69/124 (55.6%)	95/155 (61.3%)	73/134 (54.5%)	20/88 (22.7%)	47/98 (48.0%)
Week 65 (Injection #9)	1380/1613 (85.6%)	161/175 (92.0%)	119/124 (96.0%)	102/154 (66.2%)	91/132 (68.9%)	80/88 (90.9%)	80/97 (82.5%)
2 weeks post-injection	689/1591 (43.3%)	70/175 (40.0%)	48/124 (38.7%)	85/154 (55.2%)	52/127 (40.9%)	20/83 (24.1%)	36/93 (38.7%)
Week 73 (Injection #10)	1251/1585 (78.9%)	152/175 (86.9%)	115/124 (92.7%)	76/153 (49.7%)	67/124 (54.0%)	67/82 (81.7%)	71/93 (76.3%)
2 weeks post-injection	479/1571 (30.5%)	54/174 (31.0%)	36/122 (29.5%)	33/152 (21.7%)	31/123 (25.2%)	17/79 (21.5%)	20/90 (22.2%)
Week 81 (Injection #11)	1252/1568 (79.8%)	150/174 (86.2%)	115/122 (94.3%)	80/152 (52.6%)	67/122 (54.9%)	68/79 (86.1%)	73/90 (81.1%)
2 weeks post-injection	377/1543 (24.4%)	48/170 (28.2%)	19/120 (15.8%)	33/151 (21.9%)	16/120 (13.3%)	18/77 (23.4%)	14/88 (15.9%)
Week 89 (Injection #12)	1269/1537 (82.6%)	145/169 (85.8%)	111/120 (92.5%)	114/149 (76.5%)	65/120 (54.2%)	68/74 (91.9%)	68/88 (77.3%)
2 weeks post-injection	259/1521 (17.0%)	28/167 (16.8%)	7/120 (5.8%)	30/149 (20.1%)	9/118 (7.6%)	7/72 (9.7%)	7/86 (8.1%)
Week 97 (Injection #13)	1135/1514 (75.0%)	129/166 (77.7%)	99/119 (83.2%)	84/149 (56.4%)	69/117 (59.0%)	63/71 (88.7%)	56/84 (66.7%)
2 weeks post-injection	115/1502 (7.7%)	23/166 (13.9%)	1/118 (0.8%)	0/148 (0.0%)	0/113 (0.0%)	0/69 (0.0%)	1/83 (1.2%)
Week 105 (Injection #14)	1046/1500 (69.7%)	115/166 (69.3%)	80/118 (67.8%)	86/148 (58.1%)	64/113 (56.6%)	65/69 (94.2%)	61/82 (74.4%)

¹ "Visit Completion" is defined as the number (and %) of participants who completed the visit among the participants who are expected according to the protocol schedule, plus any participants who have completed the visit even though their visit window has not yet closed. "Expected according to the protocol schedule" in step 2 refers to all participants who are active (Alive, HIV uninfected, have not permanently discontinued randomized study product, and not terminated from study) at the time of the visit and the visit window has closed. Participants who transitioned early to step 3 or annual follow-up are "expected" if they are alive, HIV uninfected and not terminated from the study at the time of the visit and the visit window has closed.

² Inappropriately enrolled participants and participants with invalid ID due to duplicate screening or enrollment are excluded.

HPTN 083 – A Phase 2b/3 Double Blind Safety and Efficacy Study of Injectable Cabotegravir Compared to Daily Oral Tenofovir Disoproxil Fumarate/ Emtricitabine (TDF/FTC), For Pre-Exposure Prophylaxis in HIV-Uninfected Cisgender Men and Transgender Women who have Sex with Men
LIVE Open Report – March 5, 2026
Visit Cutoff Date: March 5, 2026

Table O7B – Visit Completion by Visit and Site – Region: Latin America ¹

	Overall	Buenos Aires – Fundacion Huesped	Buenos Aires – Hospital JM Ramos Mejia	Iquitos	Lima – Barranco	Lima – CITBM	Lima – San Miguel
2 weeks post-injection	50/1484 (3.4%)	15/166 (9.0%)	0/118 (0.0%)	0/147 (0.0%)	0/109 (0.0%)	0/67 (0.0%)	0/81 (0.0%)
Week 113 (Injection #15)	975/1479 (65.9%)	93/165 (56.4%)	73/118 (61.9%)	102/147 (69.4%)	70/109 (64.2%)	64/67 (95.5%)	59/81 (72.8%)
2 weeks post-injection	23/1467 (1.6%)	4/163 (2.5%)	0/118 (0.0%)	0/147 (0.0%)	0/108 (0.0%)	0/66 (0.0%)	0/76 (0.0%)
Week 121 (Injection #16)	861/1467 (58.7%)	69/163 (42.3%)	52/118 (44.1%)	98/147 (66.7%)	71/108 (65.7%)	60/66 (90.9%)	56/76 (73.7%)
2 weeks post-injection	7/1458 (0.5%)	0/163 (0.0%)	0/117 (0.0%)	0/147 (0.0%)	0/107 (0.0%)	0/63 (0.0%)	0/75 (0.0%)
Week 129 (Injection #17)	762/1457 (52.3%)	51/163 (31.3%)	36/117 (30.8%)	89/147 (60.5%)	72/107 (67.3%)	56/63 (88.9%)	53/75 (70.7%)
2 weeks post-injection	0/1439 (0.0%)	0/162 (0.0%)	0/117 (0.0%)	0/142 (0.0%)	0/102 (0.0%)	0/60 (0.0%)	0/75 (0.0%)
Week 137 (Injection #18)	706/1425 (49.5%)	46/152 (30.3%)	24/117 (20.5%)	84/142 (59.2%)	76/102 (74.5%)	53/60 (88.3%)	51/75 (68.0%)
2 weeks post-injection	0/1414 (0.0%)	0/149 (0.0%)	0/117 (0.0%)	0/140 (0.0%)	0/101 (0.0%)	0/59 (0.0%)	0/75 (0.0%)
Week 145 (Injection #19)	617/1412 (43.7%)	28/148 (18.9%)	9/117 (7.7%)	78/140 (55.7%)	78/101 (77.2%)	52/59 (88.1%)	55/75 (73.3%)
2 weeks post-injection	0/1398 (0.0%)	0/148 (0.0%)	0/116 (0.0%)	0/135 (0.0%)	0/97 (0.0%)	0/59 (0.0%)	0/72 (0.0%)
Week 153 (Injection #20)	525/1398 (37.6%)	26/148 (17.6%)	2/116 (1.7%)	76/135 (56.3%)	72/97 (74.2%)	46/59 (78.0%)	53/72 (73.6%)
2 weeks post-injection	0/1357 (0.0%)	0/142 (0.0%)	0/112 (0.0%)	0/130 (0.0%)	0/95 (0.0%)	0/57 (0.0%)	0/71 (0.0%)
Week 161 (Injection #21)	0/1269 (0.0%)	0/137 (0.0%)	0/102 (0.0%)	0/130 (0.0%)	0/95 (0.0%)	0/38 (0.0%)	0/66 (0.0%)
2 weeks post-injection	0/1189 (0.0%)	0/130 (0.0%)	0/99 (0.0%)	0/130 (0.0%)	0/94 (0.0%)	0/30 (0.0%)	0/64 (0.0%)
Step 3 (Open-label TDF/FTC)							
Step 3 Week 12	503/664 (75.8%)	20/27 (74.1%)	5/6 (83.3%)	86/99 (86.9%)	70/86 (81.4%)	33/40 (82.5%)	67/79 (84.8%)
Step 3 Week 24	367/583 (63.0%)	5/24 (20.8%)	4/6 (66.7%)	74/86 (86.0%)	51/66 (77.3%)	22/26 (84.6%)	46/64 (71.9%)
Step 3 Week 36	304/526 (57.8%)	5/24 (20.8%)	3/5 (60.0%)	72/82 (87.8%)	35/48 (72.9%)	18/20 (90.0%)	47/54 (87.0%)
Step 3 Week 48	253/451 (56.1%)	7/23 (30.4%)	1/5 (20.0%)	51/59 (86.4%)	30/33 (90.9%)	17/20 (85.0%)	36/42 (85.7%)
Annual Follow-up							
Yearly visit 1	82/152 (53.9%)	5/6 (83.3%)	0/0 (-%)	5/21 (23.8%)	14/27 (51.9%)	9/9 (100.0%)	11/20 (55.0%)
Yearly visit 2	37/97 (38.1%)	2/4 (50.0%)	0/0 (-%)	1/12 (8.3%)	5/17 (29.4%)	3/3 (100.0%)	4/10 (40.0%)
Yearly visit 3	17/44 (38.6%)	1/2 (50.0%)	0/0 (-%)	1/6 (16.7%)	2/10 (20.0%)	1/1 (100.0%)	2/5 (40.0%)
Yearly visit 4	0/0 (-%)	0/0 (-%)	0/0 (-%)	0/0 (-%)	0/0 (-%)	0/0 (-%)	0/0 (-%)
All visits							
Number of visits completed	45091/79592 (56.7%)	4706/8399 (56.0%)	3280/5994 (54.7%)	4288/7961 (53.9%)	3753/6462 (58.1%)	2628/4080 (64.4%)	2999/4908 (61.1%)

¹ "Visit Completion" is defined as the number (and %) of participants who completed the visit among the participants who are expected according to the protocol schedule, plus any participants who have completed the visit even though their visit window has not yet closed. "Expected according to the protocol schedule" in step 2 refers to all participants who are active (Alive, HIV uninfected, have not permanently discontinued randomized study product, and not terminated from study) at the time of the visit and the visit window has closed. Participants who transitioned early to step 3 or annual follow-up are "expected" if they are alive, HIV uninfected and not terminated from the study at the time of the visit and the visit window has closed.

² Inappropriately enrolled participants and participants with invalid ID due to duplicate screening or enrollment are excluded.

HPTN 083 – A Phase 2b/3 Double Blind Safety and Efficacy Study of Injectable Cabotegravir Compared to Daily Oral Tenofovir Disoproxil Fumarate/ Emtricitabine (TDF/FTC), For Pre-Exposure Prophylaxis in HIV-Uninfected Cisgender Men and Transgender Women who have Sex with Men
LIVE Open Report – March 5, 2026
Visit Cutoff Date: March 5, 2026

Table O7B – Visit Completion by Visit and Site – Region: Latin America ¹

	Lima – Via Libre	Porto Alegre	Rio de Janeiro	Sao Paulo – DST-AIDS	Sao Paulo – IC-HCFMUSP
Step 1					
Total participants enrolled ²	176	215	240	155	186
Week 2	168/176 (95.5%)	207/214 (96.7%)	224/238 (94.1%)	150/152 (98.7%)	183/186 (98.4%)
Week 4	170/172 (98.8%)	204/211 (96.7%)	237/237 (100.0%)	148/149 (99.3%)	184/186 (98.9%)
Step 2					
Week 5 (Injection #1)	158/161 (98.1%)	204/204 (100.0%)	230/230 (100.0%)	143/143 (100.0%)	179/181 (98.9%)
1 week post-injection	158/161 (98.1%)	203/204 (99.5%)	225/230 (97.8%)	143/143 (100.0%)	177/181 (97.8%)
Week 9 (Injection #2)	150/160 (93.8%)	201/203 (99.0%)	223/229 (97.4%)	142/143 (99.3%)	168/180 (93.3%)
1 week post-injection	147/158 (93.0%)	201/203 (99.0%)	212/227 (93.4%)	140/142 (98.6%)	167/179 (93.3%)
Week 17 (Injection #3)	142/155 (91.6%)	198/202 (98.0%)	213/227 (93.8%)	134/139 (96.4%)	158/179 (88.3%)
2 weeks post-injection	140/153 (91.5%)	197/200 (98.5%)	207/227 (91.2%)	134/139 (96.4%)	154/178 (86.5%)
Week 25 (Injection #4)	138/152 (90.8%)	191/197 (97.0%)	211/227 (93.0%)	129/137 (94.2%)	154/177 (87.0%)
2 weeks post-injection	136/150 (90.7%)	188/194 (96.9%)	204/227 (89.9%)	126/135 (93.3%)	152/176 (86.4%)
Week 33 (Injection #5)	136/149 (91.3%)	184/190 (96.8%)	216/225 (96.0%)	126/134 (94.0%)	138/173 (79.8%)
2 weeks post-injection	130/149 (87.2%)	182/189 (96.3%)	191/225 (84.9%)	121/133 (91.0%)	130/173 (75.1%)
Week 41 (Injection #6)	131/149 (87.9%)	184/189 (97.4%)	208/223 (93.3%)	123/132 (93.2%)	136/172 (79.1%)
2 weeks post-injection	115/149 (77.2%)	172/189 (91.0%)	166/222 (74.8%)	79/131 (60.3%)	100/171 (58.5%)
Week 49 (Injection #7)	113/149 (75.8%)	181/187 (96.8%)	197/220 (89.5%)	121/130 (93.1%)	132/171 (77.2%)
2 weeks post-injection	91/149 (61.1%)	155/187 (82.9%)	148/219 (67.6%)	36/127 (28.3%)	70/171 (40.9%)
Week 57 (Injection #8)	128/148 (86.5%)	183/187 (97.9%)	199/219 (90.9%)	119/127 (93.7%)	130/169 (76.9%)
2 weeks post-injection	87/147 (59.2%)	151/187 (80.7%)	146/219 (66.7%)	13/124 (10.5%)	55/167 (32.9%)
Week 65 (Injection #9)	125/147 (85.0%)	179/186 (96.2%)	195/219 (89.0%)	114/124 (91.9%)	134/167 (80.2%)
2 weeks post-injection	74/147 (50.3%)	131/180 (72.8%)	135/217 (62.2%)	2/124 (1.6%)	36/167 (21.6%)
Week 73 (Injection #10)	108/147 (73.5%)	173/179 (96.6%)	183/217 (84.3%)	111/124 (89.5%)	128/167 (76.6%)
2 weeks post-injection	47/147 (32.0%)	104/178 (58.4%)	115/216 (53.2%)	0/124 (0.0%)	22/166 (13.3%)
Week 81 (Injection #11)	102/146 (69.9%)	171/178 (96.1%)	183/215 (85.1%)	109/124 (87.9%)	134/166 (80.7%)
2 weeks post-injection	25/144 (17.4%)	90/177 (50.8%)	99/214 (46.3%)	0/119 (0.0%)	15/163 (9.2%)
Week 89 (Injection #12)	114/144 (79.2%)	169/177 (95.5%)	180/214 (84.1%)	104/119 (87.4%)	131/163 (80.4%)
2 weeks post-injection	18/143 (12.6%)	73/176 (41.5%)	71/211 (33.6%)	0/117 (0.0%)	9/162 (5.6%)
Week 97 (Injection #13)	105/143 (73.4%)	162/175 (92.6%)	169/211 (80.1%)	73/117 (62.4%)	126/162 (77.8%)
2 weeks post-injection	0/143 (0.0%)	45/175 (25.7%)	45/210 (21.4%)	0/117 (0.0%)	0/160 (0.0%)
Week 105 (Injection #14)	113/143 (79.0%)	150/174 (86.2%)	160/210 (76.2%)	30/117 (25.6%)	122/160 (76.3%)

¹ "Visit Completion" is defined as the number (and %) of participants who completed the visit among the participants who are expected according to the protocol schedule, plus any participants who have completed the visit even though their visit window has not yet closed. "Expected according to the protocol schedule" in step 2 refers to all participants who are active (Alive, HIV uninfected, have not permanently discontinued randomized study product, and not terminated from study) at the time of the visit and the visit window has closed. Participants who transitioned early to step 3 or annual follow-up are "expected" if they are alive, HIV uninfected and not terminated from the study at the time of the visit and the visit window has closed.

² Inappropriately enrolled participants and participants with invalid ID due to duplicate screening or enrollment are excluded.

HPTN 083 – A Phase 2b/3 Double Blind Safety and Efficacy Study of Injectable Cabotegravir Compared to Daily Oral Tenofovir Disoproxil Fumarate/ Emtricitabine (TDF/FTC), For Pre-Exposure Prophylaxis in HIV-Uninfected Cisgender Men and Transgender Women who have Sex with Men
LIVE Open Report – March 5, 2026
Visit Cutoff Date: March 5, 2026

Table O7B – Visit Completion by Visit and Site – Region: Latin America ¹

	Lima – Via Libre	Porto Alegre	Rio de Janeiro	Sao Paulo – DST-AIDS	Sao Paulo – IC-HCFMUSP
2 weeks post-injection	0/141 (0.0%)	10/174 (5.7%)	25/206 (12.1%)	0/117 (0.0%)	0/158 (0.0%)
Week 113 (Injection #15)	117/141 (83.0%)	138/170 (81.2%)	144/206 (69.9%)	14/117 (12.0%)	101/158 (63.9%)
2 weeks post-injection	0/141 (0.0%)	1/168 (0.6%)	18/206 (8.7%)	0/117 (0.0%)	0/157 (0.0%)
Week 121 (Injection #16)	117/141 (83.0%)	125/168 (74.4%)	135/206 (65.5%)	1/117 (0.9%)	77/157 (49.0%)
2 weeks post-injection	0/139 (0.0%)	0/167 (0.0%)	7/206 (3.4%)	0/117 (0.0%)	0/157 (0.0%)
Week 129 (Injection #17)	112/139 (80.6%)	105/166 (63.3%)	130/206 (63.1%)	0/117 (0.0%)	58/157 (36.9%)
2 weeks post-injection	0/138 (0.0%)	0/165 (0.0%)	0/204 (0.0%)	0/117 (0.0%)	0/157 (0.0%)
Week 137 (Injection #18)	116/138 (84.1%)	89/165 (53.9%)	117/200 (58.5%)	0/117 (0.0%)	50/157 (31.8%)
2 weeks post-injection	0/137 (0.0%)	0/163 (0.0%)	0/199 (0.0%)	0/117 (0.0%)	0/157 (0.0%)
Week 145 (Injection #19)	115/137 (83.9%)	71/162 (43.8%)	106/199 (53.3%)	0/117 (0.0%)	25/157 (15.9%)
2 weeks post-injection	0/137 (0.0%)	0/162 (0.0%)	0/198 (0.0%)	0/117 (0.0%)	0/157 (0.0%)
Week 153 (Injection #20)	110/137 (80.3%)	44/162 (27.2%)	80/198 (40.4%)	0/117 (0.0%)	16/157 (10.2%)
2 weeks post-injection	0/137 (0.0%)	0/161 (0.0%)	0/191 (0.0%)	0/104 (0.0%)	0/157 (0.0%)
Week 161 (Injection #21)	0/136 (0.0%)	0/152 (0.0%)	0/187 (0.0%)	0/85 (0.0%)	0/141 (0.0%)
2 weeks post-injection	0/136 (0.0%)	0/145 (0.0%)	0/177 (0.0%)	0/64 (0.0%)	0/120 (0.0%)
Step 3 (Open-label TDF/FTC)					
Step 3 Week 12	116/127 (91.3%)	16/54 (29.6%)	62/102 (60.8%)	6/8 (75.0%)	22/36 (61.1%)
Step 3 Week 24	101/112 (90.2%)	7/54 (13.0%)	39/101 (38.6%)	5/8 (62.5%)	13/36 (36.1%)
Step 3 Week 36	86/98 (87.8%)	6/54 (11.1%)	17/98 (17.3%)	5/8 (62.5%)	10/35 (28.6%)
Step 3 Week 48	86/88 (97.7%)	5/54 (9.3%)	6/96 (6.3%)	4/8 (50.0%)	10/23 (43.5%)
Annual Follow-up					
Yearly visit 1	18/25 (72.0%)	5/17 (29.4%)	7/9 (77.8%)	4/8 (50.0%)	4/10 (40.0%)
Yearly visit 2	12/22 (54.5%)	2/12 (16.7%)	4/6 (66.7%)	1/5 (20.0%)	3/6 (50.0%)
Yearly visit 3	5/11 (45.5%)	1/3 (33.3%)	2/3 (66.7%)	0/0 (–%)	2/3 (66.7%)
Yearly visit 4	0/0 (–%)	0/0 (–%)	0/0 (–%)	0/0 (–%)	0/0 (–%)
All visits					
Number of visits completed	4561/7797 (58.5%)	5676/9176 (61.9%)	6334/10995 (57.6%)	2865/5729 (50.0%)	4001/8091 (49.5%)

¹ "Visit Completion" is defined as the number (and %) of participants who completed the visit among the participants who are expected according to the protocol schedule, plus any participants who have completed the visit even though their visit window has not yet closed. "Expected according to the protocol schedule" in step 2 refers to all participants who are active (Alive, HIV uninfected, have not permanently discontinued randomized study product, and not terminated from study) at the time of the visit and the visit window has closed. Participants who transitioned early to step 3 or annual follow-up are "expected" if they are alive, HIV un-infected and not terminated from the study at the time of the visit and the visit window has closed.

² Inappropriately enrolled participants and participants with invalid ID due to duplicate screening or enrollment are excluded.

HPTN 083 – A Phase 2b/3 Double Blind Safety and Efficacy Study of Injectable Cabotegravir Compared to Daily Oral Tenofovir Disoproxil Fumarate/ Emtricitabine (TDF/FTC), For Pre-Exposure Prophylaxis in HIV-Uninfected Cisgender Men and Transgender Women who have Sex with Men
LIVE Open Report – March 5, 2026
Visit Cutoff Date: March 5, 2026

Table O7C – Visit Completion by Visit and Site – Region: Asia ¹

	Overall	Bangkok – Silom Clinic	Bangkok – Thai Red Cross	Chiang Mai	Hanoi
Step 1					
Total participants enrolled ²	752	203	210	140	199
Week 2	742/750 (98.9%)	203/203 (100.0%)	204/209 (97.6%)	138/139 (99.3%)	197/199 (99.0%)
Week 4	738/741 (99.6%)	200/200 (100.0%)	203/205 (99.0%)	137/137 (100.0%)	198/199 (99.5%)
Step 2					
Week 5 (Injection #1)	732/732 (100.0%)	197/197 (100.0%)	201/201 (100.0%)	137/137 (100.0%)	197/197 (100.0%)
1 week post-injection	718/732 (98.1%)	197/197 (100.0%)	188/201 (93.5%)	136/137 (99.3%)	197/197 (100.0%)
Week 9 (Injection #2)	722/727 (99.3%)	193/196 (98.5%)	197/197 (100.0%)	136/137 (99.3%)	196/197 (99.5%)
1 week post-injection	711/725 (98.1%)	193/194 (99.5%)	186/197 (94.4%)	136/137 (99.3%)	196/197 (99.5%)
Week 17 (Injection #3)	711/723 (98.3%)	191/193 (99.0%)	191/196 (97.4%)	136/137 (99.3%)	193/197 (98.0%)
2 weeks post-injection	703/716 (98.2%)	191/192 (99.5%)	187/194 (96.4%)	134/135 (99.3%)	191/195 (97.9%)
Week 25 (Injection #4)	695/712 (97.6%)	190/192 (99.0%)	186/193 (96.4%)	132/134 (98.5%)	187/193 (96.9%)
2 weeks post-injection	681/705 (96.6%)	189/191 (99.0%)	173/190 (91.1%)	132/134 (98.5%)	187/190 (98.4%)
Week 33 (Injection #5)	676/695 (97.3%)	185/187 (98.9%)	175/186 (94.1%)	132/134 (98.5%)	184/188 (97.9%)
2 weeks post-injection	658/692 (95.1%)	185/186 (99.5%)	163/186 (87.6%)	132/134 (98.5%)	178/186 (95.7%)
Week 41 (Injection #6)	668/689 (97.0%)	185/186 (99.5%)	177/185 (95.7%)	130/132 (98.5%)	176/186 (94.6%)
2 weeks post-injection	642/678 (94.7%)	183/183 (100.0%)	164/184 (89.1%)	129/131 (98.5%)	166/180 (92.2%)
Week 49 (Injection #7)	651/674 (96.6%)	176/182 (96.7%)	175/183 (95.6%)	128/130 (98.5%)	172/179 (96.1%)
2 weeks post-injection	615/667 (92.2%)	176/180 (97.8%)	155/181 (85.6%)	128/130 (98.5%)	156/176 (88.6%)
Week 57 (Injection #8)	627/664 (94.4%)	169/180 (93.9%)	168/181 (92.8%)	126/130 (96.9%)	164/173 (94.8%)
2 weeks post-injection	577/658 (87.7%)	169/179 (94.4%)	135/180 (75.0%)	124/127 (97.6%)	149/172 (86.6%)
Week 65 (Injection #9)	624/658 (94.8%)	173/179 (96.6%)	165/180 (91.7%)	127/127 (100.0%)	159/172 (92.4%)
2 weeks post-injection	535/647 (82.7%)	170/176 (96.6%)	127/175 (72.6%)	111/127 (87.4%)	127/169 (75.1%)
Week 73 (Injection #10)	611/645 (94.7%)	166/176 (94.3%)	161/174 (92.5%)	126/126 (100.0%)	158/169 (93.5%)
2 weeks post-injection	464/641 (72.4%)	160/174 (92.0%)	99/174 (56.9%)	98/126 (77.8%)	107/167 (64.1%)
Week 81 (Injection #11)	603/639 (94.4%)	163/172 (94.8%)	157/174 (90.2%)	125/126 (99.2%)	158/167 (94.6%)
2 weeks post-injection	398/632 (63.0%)	130/170 (76.5%)	92/172 (53.5%)	83/126 (65.9%)	93/164 (56.7%)
Week 89 (Injection #12)	589/631 (93.3%)	162/170 (95.3%)	152/171 (88.9%)	122/126 (96.8%)	153/164 (93.3%)
2 weeks post-injection	329/627 (52.5%)	112/167 (67.1%)	71/170 (41.8%)	71/126 (56.3%)	75/164 (45.7%)
Week 97 (Injection #13)	585/624 (93.8%)	160/167 (95.8%)	149/169 (88.2%)	125/126 (99.2%)	151/162 (93.2%)
2 weeks post-injection	281/618 (45.5%)	97/167 (58.1%)	65/168 (38.7%)	63/124 (50.8%)	56/159 (35.2%)
Week 105 (Injection #14)	561/617 (90.9%)	157/166 (94.6%)	143/168 (85.1%)	123/124 (99.2%)	138/159 (86.8%)
2 weeks post-injection	198/609 (32.5%)	76/164 (46.3%)	45/166 (27.1%)	40/123 (32.5%)	37/156 (23.7%)

¹ "Visit Completion" is defined as the number (and %) of participants who completed the visit among the participants who are expected according to the protocol schedule, plus any participants who have completed the visit even though their visit window has not yet closed. "Expected according to the protocol schedule" in step 2 refers to all participants who are active (Alive, HIV uninfected, have not permanently discontinued randomized study product, and not terminated from study) at the time of the visit and the visit window has closed. Participants who transitioned early to step 3 or annual follow-up are "expected" if they are alive, HIV uninfected and not terminated from the study at the time of the visit and the visit window has closed.

² Inappropriately enrolled participants and participants with invalid ID due to duplicate screening or enrollment are excluded.

HPTN 083 – A Phase 2b/3 Double Blind Safety and Efficacy Study of Injectable Cabotegravir Compared to Daily Oral Tenofovir Disoproxil Fumarate/ Emtricitabine (TDF/FTC), For Pre-Exposure Prophylaxis in HIV-Uninfected Cisgender Men and Transgender Women who have Sex with Men
LIVE Open Report – March 5, 2026
Visit Cutoff Date: March 5, 2026

Table O7C – Visit Completion by Visit and Site – Region: Asia ¹

	Overall	Bangkok – Silom Clinic	Bangkok – Thai Red Cross	Chiang Mai	Hanoi
Week 113 (Injection #15)	542/609 (89.0%)	150/164 (91.5%)	140/166 (84.3%)	115/123 (93.5%)	137/156 (87.8%)
2 weeks post-injection	145/606 (23.9%)	65/164 (39.6%)	30/165 (18.2%)	29/121 (24.0%)	21/156 (13.5%)
Week 121 (Injection #16)	525/606 (86.6%)	155/164 (94.5%)	127/165 (77.0%)	117/121 (96.7%)	126/156 (80.8%)
2 weeks post-injection	96/599 (16.0%)	46/164 (28.0%)	21/164 (12.8%)	23/120 (19.2%)	6/151 (4.0%)
Week 129 (Injection #17)	485/597 (81.2%)	154/163 (94.5%)	113/164 (68.9%)	114/119 (95.8%)	104/151 (68.9%)
2 weeks post-injection	57/593 (9.6%)	31/161 (19.3%)	7/162 (4.3%)	19/119 (16.0%)	0/151 (0.0%)
Week 137 (Injection #18)	445/593 (75.0%)	154/161 (95.7%)	104/162 (64.2%)	105/119 (88.2%)	82/151 (54.3%)
2 weeks post-injection	23/578 (4.0%)	12/160 (7.5%)	4/151 (2.6%)	7/117 (6.0%)	0/150 (0.0%)
Week 145 (Injection #19)	410/578 (70.9%)	149/160 (93.1%)	94/151 (62.3%)	94/117 (80.3%)	73/150 (48.7%)
2 weeks post-injection	2/568 (0.4%)	0/157 (0.0%)	2/150 (1.3%)	0/114 (0.0%)	0/147 (0.0%)
Week 153 (Injection #20)	354/568 (62.3%)	149/157 (94.9%)	75/150 (50.0%)	77/114 (67.5%)	53/147 (36.1%)
2 weeks post-injection	0/552 (0.0%)	0/154 (0.0%)	0/150 (0.0%)	0/111 (0.0%)	0/137 (0.0%)
Week 161 (Injection #21)	0/547 (0.0%)	0/154 (0.0%)	0/150 (0.0%)	0/111 (0.0%)	0/132 (0.0%)
2 weeks post-injection	0/536 (0.0%)	0/154 (0.0%)	0/144 (0.0%)	0/111 (0.0%)	0/127 (0.0%)
Step 3 (Open-label TDF/FTC)					
Step 3 Week 12	350/457 (76.6%)	153/190 (80.5%)	78/100 (78.0%)	80/97 (82.5%)	39/70 (55.7%)
Step 3 Week 24	291/451 (64.5%)	150/186 (80.6%)	53/100 (53.0%)	65/96 (67.7%)	23/69 (33.3%)
Step 3 Week 36	217/424 (51.2%)	137/167 (82.0%)	33/98 (33.7%)	39/91 (42.9%)	8/68 (11.8%)
Step 3 Week 48	78/353 (22.1%)	20/114 (17.5%)	17/98 (17.3%)	31/74 (41.9%)	10/67 (14.9%)
Annual Follow-up					
Yearly visit 1	30/44 (68.2%)	14/21 (66.7%)	6/9 (66.7%)	4/5 (80.0%)	6/9 (66.7%)
Yearly visit 2	13/22 (59.1%)	8/14 (57.1%)	3/4 (75.0%)	1/2 (50.0%)	1/2 (50.0%)
Yearly visit 3	2/10 (20.0%)	0/6 (0.0%)	1/2 (50.0%)	0/1 (0.0%)	1/1 (100.0%)
Yearly visit 4	0/3 (0.0%)	0/3 (0.0%)	0/0 (–%)	0/0 (–%)	0/0 (–%)
All visits					
Number of visits completed	22883/34044 (67.2%)	6854/9515 (72.0%)	5781/9178 (63.0%)	4661/6704 (69.5%)	5587/8647 (64.6%)

¹ "Visit Completion" is defined as the number (and %) of participants who completed the visit among the participants who are expected according to the protocol schedule, plus any participants who have completed the visit even though their visit window has not yet closed. "Expected according to the protocol schedule" in step 2 refers to all participants who are active (Alive, HIV uninfected, have not permanently discontinued randomized study product, and not terminated from study) at the time of the visit and the visit window has closed. Participants who transitioned early to step 3 or annual follow-up are "expected" if they are alive, HIV un-infected and not terminated from the study at the time of the visit and the visit window has closed.

² Inappropriately enrolled participants and participants with invalid ID due to duplicate screening or enrollment are excluded.

HPTN 083 – A Phase 2b/3 Double Blind Safety and Efficacy Study of Injectable Cabotegravir Compared to Daily Oral Tenofovir Disoproxil Fumarate/ Emtricitabine (TDF/FTC), For Pre-Exposure Prophylaxis in HIV-Uninfected Cisgender Men and Transgender Women who have Sex with Men
LIVE Open Report – March 5, 2026
Visit Cutoff Date: March 5, 2026

Table O7D – Visit Completion by Visit and Site – Region: Africa ¹

	Overall	Cape Town
Step 1		
Total participants enrolled ²	152	152
Week 2	143/150 (95.3%)	143/150 (95.3%)
Week 4	140/147 (95.2%)	140/147 (95.2%)
Step 2		
Week 5 (Injection #1)	129/129 (100.0%)	129/129 (100.0%)
1 week post-injection	128/129 (99.2%)	128/129 (99.2%)
Week 9 (Injection #2)	122/128 (95.3%)	122/128 (95.3%)
1 week post-injection	116/126 (92.1%)	116/126 (92.1%)
Week 17 (Injection #3)	115/124 (92.7%)	115/124 (92.7%)
2 weeks post-injection	109/124 (87.9%)	109/124 (87.9%)
Week 25 (Injection #4)	118/124 (95.2%)	118/124 (95.2%)
2 weeks post-injection	108/121 (89.3%)	108/121 (89.3%)
Week 33 (Injection #5)	110/119 (92.4%)	110/119 (92.4%)
2 weeks post-injection	105/118 (89.0%)	105/118 (89.0%)
Week 41 (Injection #6)	108/117 (92.3%)	108/117 (92.3%)
2 weeks post-injection	99/116 (85.3%)	99/116 (85.3%)
Week 49 (Injection #7)	109/115 (94.8%)	109/115 (94.8%)
2 weeks post-injection	92/113 (81.4%)	92/113 (81.4%)
Week 57 (Injection #8)	104/109 (95.4%)	104/109 (95.4%)
2 weeks post-injection	80/109 (73.4%)	80/109 (73.4%)
Week 65 (Injection #9)	100/109 (91.7%)	100/109 (91.7%)
2 weeks post-injection	76/109 (69.7%)	76/109 (69.7%)
Week 73 (Injection #10)	100/108 (92.6%)	100/108 (92.6%)
2 weeks post-injection	68/106 (64.2%)	68/106 (64.2%)
Week 81 (Injection #11)	95/105 (90.5%)	95/105 (90.5%)
2 weeks post-injection	60/104 (57.7%)	60/104 (57.7%)
Week 89 (Injection #12)	92/104 (88.5%)	92/104 (88.5%)
2 weeks post-injection	45/104 (43.3%)	45/104 (43.3%)
Week 97 (Injection #13)	90/103 (87.4%)	90/103 (87.4%)
2 weeks post-injection	36/102 (35.3%)	36/102 (35.3%)
Week 105 (Injection #14)	79/102 (77.5%)	79/102 (77.5%)
2 weeks post-injection	17/102 (16.7%)	17/102 (16.7%)
Week 113 (Injection #15)	65/102 (63.7%)	65/102 (63.7%)

¹ "Visit Completion" is defined as the number (and %) of participants who completed the visit among the participants who are expected according to the protocol schedule, plus any participants who have completed the visit even though their visit window has not yet closed. "Expected according to the protocol schedule" in step 2 refers to all participants who are active (Alive, HIV uninfected, have not permanently discontinued randomized study product, and not terminated from study) at the time of the visit and the visit window has closed. Participants who transitioned early to step 3 or annual follow-up are "expected" if they are alive, HIV un-infected and not terminated from the study at the time of the visit and the visit window has closed.

² Inappropriately enrolled participants and participants with invalid ID due to duplicate screening or enrollment are excluded.

HPTN 083 – A Phase 2b/3 Double Blind Safety and Efficacy Study of Injectable Cabotegravir Compared to Daily Oral Tenofovir Disoproxil Fumarate/ Emtricitabine (TDF/FTC), For Pre-Exposure Prophylaxis in HIV-Uninfected Cisgender Men and Transgender Women who have Sex with Men
LIVE Open Report – March 5, 2026
Visit Cutoff Date: March 5, 2026

Table O7D – Visit Completion by Visit and Site – Region: Africa ¹

	Overall	Cape Town
2 weeks post-injection	11/102 (10.8%)	11/102 (10.8%)
Week 121 (Injection #16)	60/102 (58.8%)	60/102 (58.8%)
2 weeks post-injection	8/101 (7.9%)	8/101 (7.9%)
Week 129 (Injection #17)	59/101 (58.4%)	59/101 (58.4%)
2 weeks post-injection	3/100 (3.0%)	3/100 (3.0%)
Week 137 (Injection #18)	54/95 (56.8%)	54/95 (56.8%)
2 weeks post-injection	0/95 (0.0%)	0/95 (0.0%)
Week 145 (Injection #19)	46/95 (48.4%)	46/95 (48.4%)
2 weeks post-injection	0/95 (0.0%)	0/95 (0.0%)
Week 153 (Injection #20)	43/95 (45.3%)	43/95 (45.3%)
2 weeks post-injection	0/95 (0.0%)	0/95 (0.0%)
Week 161 (Injection #21)	0/95 (0.0%)	0/95 (0.0%)
2 weeks post-injection	0/95 (0.0%)	0/95 (0.0%)
Step 3 (Open-label TDF/FTC)		
Step 3 Week 12	27/50 (54.0%)	27/50 (54.0%)
Step 3 Week 24	16/49 (32.7%)	16/49 (32.7%)
Step 3 Week 36	8/46 (17.4%)	8/46 (17.4%)
Step 3 Week 48	4/45 (8.9%)	4/45 (8.9%)
Annual Follow-up		
Yearly visit 1	1/2 (50.0%)	1/2 (50.0%)
Yearly visit 2	0/2 (0.0%)	0/2 (0.0%)
Yearly visit 3	0/1 (0.0%)	0/1 (0.0%)
Yearly visit 4	0/0 (-%)	0/0 (-%)
All visits		
Number of visits completed	3451/5705 (60.5%)	3451/5705 (60.5%)

¹ "Visit Completion" is defined as the number (and %) of participants who completed the visit among the participants who are expected according to the protocol schedule, plus any participants who have completed the visit even though their visit window has not yet closed. "Expected according to the protocol schedule" in step 2 refers to all participants who are active (Alive, HIV uninfected, have not permanently discontinued randomized study product, and not terminated from study) at the time of the visit and the visit window has closed. Participants who transitioned early to step 3 or annual follow-up are "expected" if they are alive, HIV un-infected and not terminated from the study at the time of the visit and the visit window has closed.

² Inappropriately enrolled participants and participants with invalid ID due to duplicate screening or enrollment are excluded.